

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number
WO 02/102370 A1

(51) International Patent Classification⁷: **A61K 31/365**,
31/695, 31/121, 31/19, A61P 31/04, A01N 43/08, 37/42,
35/02

(21) International Application Number: PCT/AU02/00797

(22) International Filing Date: 18 June 2002 (18.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PR 5754 18 June 2001 (18.06.2001) AU

(71) Applicant (for all designated States except US):
UNISEARCH LIMITED [AU/AU]; Rupert Myers
Building, Level 2, Gate 14, Barker Street, UNSW, Sydney,
NSW 2052 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KJELLEBERG, Staffan** [SE/AU]; 22 Goorawahl Avenue, La Perouse, NSW 2036 (AU). **GIVSKOV, Michael** [DK/DK]; Boserupvej 206, DK-3050 Humlebaek (DK). **HENTZER, Morten** [DK/DK]; Godthabsvej 39, 4 tv., DK-2000 Frederiksberg (DK).

(74) Agent: **F B RICE & CO**; 139-141 Rathdowne Street, Carlton, VIC 3053 (AU).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BIOFILM DEGRADING OR SLOUGHING COMPOSITIONS AND METHODS

(57) Abstract: The present invention relates to a method for the regulation and control of biofilm layers. In particular, the present invention is concerned with methods for degrading or causing sloughing of biofilms from surfaces. The invention is also related to compositions suitable for use in carrying out these methods.



WO 02/102370 A1

BIOFILM DEGRADING OR SLOUGHING COMPOSITIONS AND METHODS

FIELD OF THE INVENTION

The present invention relates to a method for the regulation and control
5 of biofilm layers. In particular, the present invention is concerned with methods
for degrading or causing sloughing of biofilms from surfaces. The invention is
also related to compositions suitable for use in carrying out these methods.

BACKGROUND OF THE INVENTION

10 Biofilms are biological films that can develop and persist on solid
substrates in contact with moisture, on soft tissue surfaces in living organisms
and at liquid air interfaces. They can develop into structures several millimetres
or centimetres in thickness and can cover large surface areas. They may
contain either single or multiple microbial species and readily adhere to such
15 diverse surfaces as river rocks, soil, pipelines, teeth, mucous membranes, and
medical implants.

Biofilms form along inner walls of piping conduits in industrial facilities
and in household plumbing systems. They can play a role in restricting or
entirely blocking the flow in the plumbing systems and can decrease the life of
20 materials through corrosive action mediated by embedded bacteria. Biofilms
can also result in the reduction of the efficiency of industrial processes, wasting
energy, and reducing product quality.

Biofilms frequently cause problems in cooling water systems used in
power-generating plants, refineries, chemical plants, and air conditioning
25 systems. Cooling water systems are often contaminated with airborne
organisms entrained by air/water contact in cooling towers as well as
waterborne organisms from the system's makeup water supply. Biofilms can
also compromise water supplies in that they can provide a haven for disease
causing microorganisms that can proliferate despite chlorination.

30 The control and removal of biofilm material from piping conduit surface
has historically been carried out by the addition of corrosive chemicals such as
chlorine or strong alkalis or through mechanical means. Such treatments are
generally harsh to both the equipment and the environment and have been
necessary due to the recalcitrant nature of biofilms within those systems. The
35 resistance to treatment has been due in large measure to the protective
character of intact biofilm matrix polymers.

Biofilm formation also has implications in human and animal health. Biofilms can present a serious threat to health as foci of chronic infections. For example, biofilm composed of *Pseudomonas aeruginosa*, the bacterium responsible for biofilm formed in the lungs of cystic fibrosis patients, is believed to be behind the fatal lung infections in patient suffering this disease. Biofilms have been implicated in periodontal disease, tooth decay, prostate infections, kidney stones, tuberculosis, Legionnaire's disease and some infections of the middle ear.

Biofilms may also be the cause of infections resulting from medical intervention. For example, biofilms can form on medical devices including catheters, medical implants, dental equipment and contact lenses.

Commonly, patients with indwelling catheters for urine excretion, for continuous ambulatory peritoneal dialysis (CAPD) or for any other reason are subject to frequent and persistent bouts of infection. These recurrent infections are due to the accumulation of mixed biofilms on the artificial surfaces provided by the catheter or other implant. The glycocalyx in which the bacteria live protects them from the effects of antibiotics and accounts for the persistence of the infection even in the face of vigorous chemotherapy.

Biofilm formation can be a serious complication in bioimplants such as bone prosthesis, heart valves, pacemakers, stents, orthopaedic devices, ear implant devices, electrodes, dialysis devices and the like. Biofilm formation on exposed surfaces of a bioimplant can degrade the function of the implant, as in the case of implanted valves, lead to serious joint or bone infections, as in the case of a bone prosthesis, and in all cases, provide a source of difficult to treat septic infection.

Infections due to microbial keratitis, acanthamoeba or ulcerative keratitis are recurring problems associated with contact lens wear. The problems may arise for example when a contact lens is not cleansed sufficiently by the lens wearer, and the bacterial load of the lens increases such that a biofilm forms on the lens. In such cases not all lens cleaning solutions may be strong enough to kill residual bacteria. Similarly the contact lens may harbour infectious organisms such as acanthamoeba, which can also contaminate the lens case in addition to the lens resulting in time in a devastating keratitis.

Biofilm-derived dental unit waterline contamination is a problem in the dental industry. The formation of biofilms provides the potential for exposure of

dental personnel and patients to high concentrations of microbes that may present a risk of infection.


Prevention of colonization by and eradication of biofilm-associated microorganisms is an important, and often difficult to solve problem in
 5 medicine. The extracellular materials (polysaccharide, proteins, etc) that make up the biofilm can be a problem in itself, eg, blockage of a catheter or by causing a spurious immune response. Generally though, the problem is that the cells within the biofilm are more resistant to a number of treatments. For example, *P. aeruginosa* is 50,000 times more resistant to the drug tobramycin
 10 when in the biofilm form compared to the planktonic cells. Thus, traditional biocides are less/not effective against the biofilm population. They are also less vulnerable to the immune system and the matrix polysaccharides of the biofilms resist enzyme attack.

There is a need in the medical, environmental and industrial arts for the
 15 control of biofilm formation. The control of biofilms can be carried out more effectively if the production and regulation of exopolysaccharide material produced by the bacteria can be influenced externally.

SUMMARY OF THE INVENTION

20 The present inventors have determined that furanones and related compounds can cause degradation or sloughing of biofilms.

Accordingly, in a first aspect the present invention consists in a method of degrading or causing sloughing of biofilms, the method comprising applying to the biofilm a composition comprising at least one compound of general
 25 formula I:




wherein R₁ is selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl or arylalkyl whether unsubstituted or substituted, optionally interrupted
 30 by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

R₂, R₃ and R₄, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl, arylalkyl, or a silyl group, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or

5 fluorophilic;

R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane; and

" " represents a single bond or a double bond,
or a compound of general formula II



II

10

wherein R₅, R₆ and R₇, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, carboxyl, acyl, acyloxy, acylamino, formyl and cyano whether unsubstituted or substituted, optionally interrupted by one or more hetero
15 atoms, straight chain or branched chain, hydrophilic, hydrophobic or fluorophilic and X is a halogen.

In one embodiment R₆ and R₇ are independently H, halogen, carboxyl, ester, formyl, cyano, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms,
20 straight chain or branched chain, hydrophilic or fluorophilic;
X is a halogen;

R₅ is H, alkyl, alkenyl, alkynyl, alkene, alkyne, aryl, arylalkyl, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic.

25 In the compound of formula I, preferably, at least one of R₁, R₂, R₃ and R₄ is bromine. Most preferably, at least one of R₃ and R₄ is Br. In the compound of formula II, preferably at least one of R₅, R₆, or R₇ is bromine.

The term "alkyl" is taken to mean both straight chain or branched alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl,
30 tertiary butyl, and the like. Preferably the alkyl group is a lower alkyl of 1 to 6 carbon atoms. The alkyl group may optionally be substituted by one or more groups selected from alkyl, cycloalkyl, alkenyl, alkynyl, halo, haloalkyl,

haloalkynyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocyclyl, heterocycloxy,

5 heterocyclamino, haloheterocyclyl, alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as phosphono and phosphinyl.

The alkyl group may also be perfluorinated.

The term "alkoxy" denotes straight chain or branched alkyloxy, preferably C₁-10 alkoxy. Examples include methoxy, ethoxy, n-propoxy, isopropoxy and
10 the different butoxy isomers.

The term "alkenyl" denotes groups formed from straight chain, branched or mono- or polycyclic alkenes and polyene. Substituents include mono- or poly-unsaturated alkyl or cycloalkyl groups as previously defined, preferably C₂-10 alkenyl. Examples of alkenyl include vinyl, allyl, 1-methylvinyl, butenyl,
15 iso-butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3-heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1,4-pentadienyl, 1,3-cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl,
20 1,3,5-cycloheptatrienyl, or 1,3,5,7-cyclooctatetraenyl.

The term "halogen" denotes fluorine, chlorine, bromine or iodine, preferably bromine or fluorine.

The term "heteroatoms" denotes O, N or S.

The term "acyl" used either alone or in compound words such as
25 "acyloxy", "acylthio", "acylamino" or diacylamino" denotes an aliphatic acyl group and an acyl group containing a heterocyclic ring which is referred to as heterocyclic acyl, preferably a C₁-10 alkanoyl. Examples of acyl include carbamoyl; straight chain or branched alkanoyl, such as formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl,
30 hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl; alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl or heptyloxycarbonyl; cycloalkanecarbonyl such as cyclopropanecarbonyl cyclobutanecarbonyl, cyclopentanecarbonyl or cyclohexanecarbonyl; alkanesulfonyl, such as methanesulfonyl or ethanesulfonyl; alkoxysulfonyl,
35 such as methoxysulfonyl or ethoxysulfonyl; heterocycloalkanecarbonyl; heterocycloalkanoyle, such as pyrrolidinylacetyl, pyrrolidinylpropanoyl,

pyrrolidinylbutanoyl, pyrrolidinylpentanoyl, pyrrolidinylhexanoyl or thiazolidinylacetyl; heterocyclylalkenoyl, such as heterocyclylpropenoyl, heterocyclylbutenoyl, heterocyclylpentenoyl or heterocyclylhexenoyl; or heterocyclylglyoxyloyl, such as, thiazolidinylglyoxyloyl or pyrrolidinylglyoxyloyl.

5 As will be recognised by those skilled in the art the compounds of general formulas I and II can exist as two isomers E and Z. Furthermore, some substituents in the side chain may result in compounds of formula I or II that have optically active enantiomers. It is intended that the general formulas depicted herein are not limited to a particular isomer and encompass both
10 isomers either in the form of a racemic mixture or separated isomers.

DETAILED DESCRIPTION OF THE INVENTION

The biofilm to be treated may be dominated or characterised by undesirable bacterial cells, for example, living cells selected from, but not
15 limited to, the bacterial genera *Pseudomonas*, *Staphylococcus*, *Aeromonas*, *Burkholderia*, *Erwinia*, *Fusobacterium*, *Helicobacter*, *Klebsiella*, *Listeria*, *Mycobacterium*, *Neisseria*, *Porphyromonas*, *Providencia*, *Ralstonia*, *Salmonella*, *Staphylococcus*, *Streptococcus*, *Vibrio*, *Xenorhabdus*, and *Yersinia*.


The biofilm may be dominated by or characterised by, but not limited to,
20 one or more of the organisms *Aeromonas hydrophila*, *A. salmonicida*, *Burkholderia cepacia*, *Enterobacter aerogenes*, *Escherichia coli*, *Erwinia carotovora*, *Fusobacterium nucleatum*, *Helicobacter pylori*, *Klebsiella pneumoniae*, *Listeria monocytogenes*, *Mycobacterium tuberculosis*, *Neisseria meningitidis*, *N. gonorrhea*, *Porphyromonas gingivalis*, *Providencia stuartii*,
25 *Pseudomonas aeruginosa*, *Ralstonia solanacearum*, *Salmonella typhimurium*, *Salmonella choleraesuis*, *Serratia liquefaciens*, *S. marcesens*, *Staphylococcus aureus*, *S. epidermidis*, *Streptococcus mutans* (*sobrinus*), *Strep. pyogenes*, *Strep pneumoniae*, *Vibrio parahaemolyticus*, *V. vulnificus*, *V. cholerae*, *V. harveyi*, *V. anguillarum*, *Xenorhabdus nemotophilus*, *Yersinia pestis*, *Y. enterocolitica*, *Y. pseudotuberculosis*
30

In an embodiment of the present invention the microorganism constituting the biofilm is *Pseudomonas* sp., particularly *Pseudomonas aeruginosa*.

In a further preferred embodiment the composition comprises at least
35 one compound 30 or 56 as set out in Table 1.

Pseudomonas biofilms are of particular concern in cystic fibrosis.

Accordingly, in a second aspect the present invention consists in a method of degrading or causing sloughing of a *Pseudomonas* biofilm in the lung of a subject suffering from cystic fibrosis, the method comprising administering to the biofilm a composition comprising at least one compound of
 5 general formula I:



10


wherein R₁ is selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or
 15 fluorophilic;

R₂, R₃ and R₄, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl, arylalkyl, or a silyl group, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or
 20 fluorophilic;

R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane; and
 "====" represents a single bond or a double bond.

or a compound of general formula II

25



wherein R₆ and R₇ are independently H, halogen, carboxyl, ester, formyl, cyano, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or


substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

X is a halogen;

- 5 R₅ is H, alkyl, alkenyl, alkynyl, alkene, alkyne, aryl, arylalkyl, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic.

As used herein the terms "degrading" or "sloughing" are intended to convey that the thickness of the biofilm is reduced or that the biofilm is disrupted.


- 10 In a third aspect, the present invention provides a biofilm degrading or sloughing composition comprising an amount of a compound comprising at least one compound of general formula I:



- 15 wherein R₁ is selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

- 20 R₂, R₃ and R₄, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl, arylalkyl, or a silyl group, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

- 25 R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane; and " " represents a single bond or a double bond, or a compound of general formula II



wherein R₅, R₆ and R₇, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, carboxyl, acyl, acyloxy, acylamino, formyl and cyano whether unsubstituted or substituted, optionally interrupted by one or more hetero
5 atoms, straight chain or branched chain, hydrophilic, hydrophobic or fluorophilic and X is a halogen,

wherein the amount of the compound(s) is effective to degrade or cause sloughing of the biofilm.

The use of compounds of formulae I and II result in the eventual loss of
10 the biofilm or make it easier to remove mechanically (eg, by wiping away in the shower/toilet or creating turbulence in fluid in a conduit). These compounds may also increase the susceptibility of the biofilm to traditional biocides (and antibiotics) in addition to helping to remove the biofilm through sloughing processes. Thus, the inclusion of adjunct therapies might have synergistic
15 effects, especially on biofilms and would certainly help in the killing of the newly removed biofilm cells.

The compositions of the third aspect of the invention may be in any suitable form. The composition may include a carrier or diluent. The carrier may be liquid or solid. For example, the compositions may be in the form of a
20 solution or suspension of the compounds in a liquid. The liquid may be an aqueous solvent or non-aqueous solvent. The liquid may consist of or comprise a one of more organic solvents. The liquid may be an ionic liquid. Particular examples of carrier or diluents include, but are not limited to, water, polyethylene glycol, propylene glycol, cyclodextrin and derivatives thereof.

25 The composition may be formulated for delivery in an aerosol or powder form.

The composition may include organic or inorganic polymeric substances. For example, the compound of formula I or II may be admixed with a polymer or bound to, or adsorbed onto, a polymer.

30 When the composition is to be formulated as a cleaning formulation, the composition may include conventional additives used in such formulations. Non-limiting examples of the physical form of the formulations include powders, solutions, suspensions, dispersions, emulsions and gels.

Formulations for pharmaceutical uses may incorporate pharmaceutically
35 acceptable carriers, diluents and excipients known to those skilled in the art. The compositions may be formulated for parenteral or non-parenteral

administration. The composition of the invention may be formulated for methods of introduction including, but not limited to, topical, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, ophthalmic, and oral routes. It may be formulated for administration by any
5 convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration may be localized or systemic. The composition may be formulated for intraventricular and intrathecal injection..
10 Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In certain preferred embodiments the composition further comprises other active agents such as antibiotics and cleaning agents. As will be understood the degradation or sloughing of the biofilm will allow greater
15 penetration of, for example, antibiotics into the biofilm enabling greater removal of the biofilm.

In a fourth aspect, the present invention provides a method of treating an infection in a human or animal subject in which a biofilm is formed, the method comprising administration to the subject of an effective amount of the
20 composition of the invention.

Biofilms are responsible for diseases such as otitis media (inflammation of the inner ear). Other diseases in which biofilms play a role include bacterial endocarditis (infection of the inner surface of the heart and its valves), cystic fibrosis (as already mentioned above), and Legionnaire's disease (an acute
25 respiratory infection). The method of the third aspect may be used to treat such medical conditions.

The method may also be used to treat biofilm formation resulting from a skin infection, burn infection and/or wound infection. The method and composition of the invention may be particularly suitable for the treatment of infection in
30 immuno compromised individuals.

In yet a fifth aspect, the present invention provides a method for treating a surface to degrade or cause sloughing of at least a portion of the biofilm formed on the surface, the method comprising contacting the surface with a compound in accordance with the present invention.

The term "surface" as used herein relates to any surface which may be covered by a biofilm layer. The surface may be a biological (eg tissue, membrane, skin etc) or non-biological surface.

The surface may be that of a natural surface, for example, plant seed,
5 wood, fibre etc.

The surface may be any hard surface such as metal, organic and inorganic polymer surface, natural and synthetic elastomers, board, glass, wood, paper, concrete, rock, marble, gypsum and ceramic materials which optionally are coated, eg with paint, enamel etc; or any soft surface such as
10 fibres of any kind (yarns, textiles, vegetable fibres, rock wool, hair etc.); or porous surfaces; skin (human or animal); keratinous materials (nails etc.). The hard surface can be present in a process equipment member of a cooling equipment, for example, a cooling tower, a water treatment plant, a dairy, a food processing plant, a chemical or pharmaceutical process plant. The porous
15 surface can be present in a filter, eg. a membrane filter.

Particular examples of surfaces that may be treated in accordance with the invention include, but are not limited to, toilet bowls, bathtubs, drains, highchairs, counter tops, vegetables, meat processing rooms, butcher shops, food preparation areas, air ducts, air-conditioners, carpets, paper or woven
20 product treatment, nappies(diapers), personal hygiene products (eg sanitary napkins) and washing machines. The cleaning composition may be in the form of a toilet drop-in or spray-on for prevention and removal of soil and under rim cleaner for toilets. The composition and method of the present invention also have application to cleaning of Industrial surfaces such as floors, benches,
25 walls and the like and these and other surfaces in medical establishments such as hospitals (eg surfaces in operating theatres), veterinary hospitals, and in mortuaries and funeral parlours.

In one embodiment, the method comprises the steps of administering a cleaning-effective amount of a furanone compound described above to a
30 biofilm-containing surface or a surface to ensure that it is biofilm-free. In another form of the present invention, one would administer an amount of the cleaning compound described above effective to prevent biofilm build-up or formation on a surface.

In particularly advantageous forms of the present invention, the method
35 is used to remove biofilm on food preparation surfaces, such as kitchen counters, cutting boards, sinks, stoves, refrigerator surfaces, or on sponges

and other cleaning implements, such as mops and wipes.

In another advantageous form of the present invention, the method is used to remove biofilm on bathroom surfaces, such as toilets, sinks, bathtubs, showers, and drains.

5 In another form, the present invention is used to remove biofilm on clothing and other woven and soft surfaces. This may be by means of a wipe, sponging or soaking method or by a laundering or detergent method. In another form of the present invention, the method is used to remove biofilm on floors and window surfaces, especially surfaces that are exposed to moisture,
10 such as kitchen floor, shower stalls, and food production areas. In another form of the present invention, the method is used to remove biofilm in large-scale sanitation applications, such as food production machinery, processing areas and conduits that carry raw materials or finished products.

The compound of the present invention may be used in the preparation
15 of epidermal bandages and lotions. Alternatively, the compounds of the invention may be incorporated into cosmetic formulations, for example, aftershave lotions.

Compositions of the present invention may be in the form of an aqueous solution or suspension containing a cleaning-effective amount of the active
20 compound described above. The cleaning composition may be in the form of a spray, a dispensable liquid, or a toilet tank drop-in under-rim product for prevention, removal and cleaning of toilets and other wet or intermittently wet surfaces in domestic or industrial environments.

The compositions of the present invention may additionally comprise a
25 surfactant selected from the group consisting of anionic, nonionic, amphoteric, biological surfactants and mixtures thereof. Most preferably, the surfactant is sodium dodecyl sulfate.

One or more adjuvant compounds may be added to the cleaning solution of the present invention. They may be selected from one or more of biocides,
30 fungicides, antibiotics, and mixtures thereof to affect planktonics. pH regulators, perfumes, dyes or colorants may also be added.

By "cleaning-effective" amount of active compound, it is meant an amount of the compound which is necessary to remove at least 10% of bacteria from a biofilm as determined by a reduction in numbers of bacteria
35 within the biofilm when compared with a biofilm not exposed to the active compound.

The cleaning methods of the present invention are suitable for cleaning biofilm deposits. They may be used to treat hard, rigid surfaces such as drain pipes, glazed ceramic, porcelain, glass, metal, wood, chrome, plastic, vinyl and formica or soft flexible surfaces such as shower curtains, upholstery, laundry
5 and carpeting. It is also envisioned that both woven and non woven and porous and non-porous surfaces would be suitable.

In other embodiments of the present invention, the composition of the invention may be formulated as a dentifrice, a mouthwash or a composition for the treatment of dental caries. The composition may be formulated for acne
10 treatment or cleaning and disinfecting contact lenses (eg as a saline solution).

The method of the invention may be used to treat biofilms on implanted devices that are permanent such as an artificial heart valve or hip joint, and those that are not permanent such as indwelling catheters, pacemakers, surgical pins etc. The method may further be used to remove
15 biofilm in situations involving bacterial infection of a host, either human or animal, for example in a topical dressing for burn patients. An example of such a situation would be the infection by *P. aeruginosa* of superficial wounds such as are found in burn patients or in the lung of a cystic fibrosis patient.

In other forms, the present invention can be used to treat biofilms developing in the process of manufacturing integrated circuits, circuit boards or other electronic or microelectronic devices.
20

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not
25 the exclusion of any other element, integer or step, or group of elements, integers or steps.

All publications mentioned in the specification are herein incorporated by reference.

Any discussion of documents, acts, materials, devices, articles or the like
30 which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

35 As indicated above, the method and compositions of the present invention have application to any biofilm. The following discussion provides a

possible explanation for the effectiveness of the compounds of the invention in causing sloughing of one particular category of biofilm forming microorganisms. However, it is to be understood that the present invention is not to be limited by this explanation or to the particular microorganisms described below.

5 Many host-associated bacteria use chemical signals to monitor their own species population density and to control expression of specific genes in response to population density. This type of gene regulation is termed quorum sensing (Fuqua *et al.*, 1997) and is a generic phenomenon described in many Gram-negative (Eberl, 1999; Greenberg, 1997) and Gram-positive bacteria
10 (Kleerebezem *et al.*, 1997). Many Gram-negative bacteria capable of quorum sensing employ acylated homoserine lactones (AHL) as the signalling compound. The various AHL compounds described in Gram-negative bacteria differ between one another in length and substitutions on their acyl side chains. The signalling molecule is synthesized by a LuxI-type synthase and they bind
15 to a cognate LuxR-type transcriptional activator protein to regulate expression of target genes. At low cell density, the signalling compound is synthesized at a low basal level and is thought to diffuse into the surrounding media where it becomes diluted. During growth, the AHL accumulates in the medium until a critical threshold concentration is reached. At this concentration, the AHL binds
20 to its cognate receptor, which in turn becomes activated and stimulates or represses transcription of target genes.

Pseudomonas aeruginosa, a Gram-negative opportunistic human pathogen, is responsible for persistent and often incurable infections in immunocompromised people and individuals with cystic fibrosis (Hoiby, 2000;
25 Koch & Hoiby, 1993; Pollack, 1990). The list of *P. aeruginosa* quorum sensing controlled (qsc) genes and phenotypes is continuously growing (Glessner *et al.*, 1999; Hassett *et al.*, 1999) and classes of qsc genes are emerging (Whiteley *et al.*, 1999). For reviews see (Passador & Iglewski, 1995; Pesci & Iglewski, 1997; Swift *et al.*, 1996; Van Delden & Iglewski, 1998; Williams *et al.*, 2000).

30 Two AHL-mediated quorum sensing circuits has been identified in *P. aeruginosa*. The *las* system consists of *lasI*, an AHL synthase gene responsible for the synthesis of OdDHL (*N*-[3-oxo-dodecanoyl]-L-homoserine lactone; 3-oxo-C12-HSL; PAI-1) (Pearson *et al.*, 1994), and *lasR* that encodes a LuxR-type transcriptional regulator protein (Gambello & Iglewski, 1991;
35 Passador *et al.*, 1993). The *las* system has been shown to regulate the expression of several virulence factors such as extracellular enzymes (LasB

elastase, LasA protease, alkaline protease), secondary metabolites (pyocyanin, hydrogen cyanide, pyoverdine), toxins (exotoxin A), and *lasI* itself. In the *rhl* system, the *rhlI* gene product directs the synthesis of BHL (*N*-butanoyl-L-homoserine lactone; C4-HSL, PAI-2), which in conjunction with the *rhlR* gene product activates transcription of the *rhlAB* rhamnolipid biosynthesis genes and the *rhlI* gene itself. The *rhl* system is also involved in modulating the expression of several of the virulence factors controlled by the *las* system (Glessner *et al.*, 1999; Pearson *et al.*, 1995).

In the CF lung, *P. aeruginosa* grows primarily as biofilms (Hoiby, 1977; Lam *et al.*, 1980; Singh *et al.*, 2000), which provides protection from the host defence system and from the action of antibiotics (Koch & Hoiby, 1993). Biofilms are highly structured, surface-attached communities of cells enclosed in self-produced polymeric matrix. In laboratory-based systems, *P. aeruginosa* forms biofilms several hundred micrometers thick with tower- and mushroom-shaped microcolonies intervened by water channels and void spaces (Costerton *et al.*, 1995; Davies *et al.*, 1998). The current model is that biofilm formation proceeds through a series of programmed events. O'Toole and Kolter (1998) have demonstrated that flagellar motility and type IV pili-mediated twitching motility in *P. aeruginosa* is necessary for surface attachment and colonization. There is compelling evidence that cell-to-cell communication plays a crucial role for the maturation of biofilms, i.e. for the development of a characteristic three-dimensional biofilm architecture. For *P. aeruginosa* it has been demonstrated that the ability to form biofilms in flow chamber systems is affected by the *las* but not the *rhl* quorum sensing system (Davies *et al.*, 1998). While the wild-type formed characteristic microcolonies separated by water channels, the *lasI* mutant developed only flat, undifferentiated biofilms, which exhibited greater sensitivity to the biocide sodium dodecyl sulfate. These results argue in favor of functional overlaps between factors necessary for cell-to-cell signalling, biofilm maturation and bacterial pathogenesis.

Phenotypes regulated by cell-to-cell communication have been proven or suggested to be important for bacterial colonization of eukaryotes (Eberl *et al.*, 1996; Givskov *et al.*, 1996; Kjelleberg *et al.*, 1997; Piper *et al.*, 1993; von Bodman & Farrand, 1995; Givskov *et al.*, 1996). Given the widespread occurrence of AHL-mediated cell-to-cell communication systems, it has been hypothesized that higher organisms may have evolved specific means to interfere with bacterial communication and possibly escape colonization. The

Australian marine macroalga *Delisea pulchra* has been suggested to possess such a countermeasure to bacterial processes (Kjelleberg *et al.*, 1997). The alga produces a number of halogenated furanones (de Nys *et al.*, 1993; Reichelt & Borowitzka, 1984) which display strong bacterial activities, including
 5 antifouling and antimicrobial properties (de Nys *et al.*, 1995; Reichelt & Borowitzka, 1984). Most interestingly, recent reports indicate that some furanones possess AHL-antagonistic activity, which likely can be attributed to a structural similarity to AHLs (Givskov *et al.*, 1996; Manefield *et al.*, 1999; Manefield *et al.*, 2000).

10

BRIEF DESCRIPTION OF FIGURES

15 **Fig. 1.** Schematic drawings of *lasB* reporter fusions (not to scale). (A) *lasB*-*gfp*(ASV) translational fusion vector pMHLB. (B) pMHLAS with *lasB* fusion and *lasR* expressed from the *lac* promoter. (C) *gfp* expression cassette of pMH306. (D) L-arabinose controlled *gfp*(ASV) expression cassette of pBADGfp. The indicated *NotI* fragments are maintained on a *Pseudomonas*-shuttle vector of
 20 the pUCP-series and on the mini-Tn5 delivery vector, pTn5-Gm. The genetic components are: *PlasB*, elastase (*LasB*) promoter fragment; *gfp*(ASV), gene encoding the unstable Gfp(ASV); *T₀*, transcriptional terminator from phage lambda, *T₁*, transcriptional terminator from *rrnB* operon of *E. coli*; *P_{A1/O4/O3}*, a strong, synthetic LacI-repressible promoter; RBSII, synthetic ribosome binding
 25 site; *araC P_{BAD}*, the promoter of the *E. coli araBAD* operon and the gene encoding the positive and negative regulator of this promoter, *araC*.

Fig. 2. Characterization of *lasB*-based quorum sensing reporter. (A) Induction of pMHLAS in *E. coli* MT102 by different AHL compounds, all at 1000 nM. The
 30 relative green fluorescence emitted by the cells was calculated as the fluorescence at 515 nm divided by the optical density at 600 nm. The AHL compounds assayed were: OdDHL (*N*-[3-oxo-dodecanoyl]-L-homoserine lactone), ODHL (*N*-[3-oxo-decanoyl]-L-homoserine lactone), DHL (*N*-decanoyl-L-homoserine lactone), OOHl (*N*-[3-oxo-octanoyl]-L-homoserine lactone), OHL
 35 (*N*-octanoyl-L-homoserine lactone), OHHL (*N*-[3-oxo-hexanoyl]-L-homoserine lactone), HHL (*N*-hexanoyl-L-homoserine lactone), BHL (*N*-butanoyl-L-

homoserine lactone). The results are mean \pm SEM of three independent experiments. (B) OdDHL-mediated induction of the *PlasB-gfp(ASV) Plac-lasR* reporter cassette on a mini-Tn5 transposon integrated into the chromosome of PAO-JP2. The results are mean \pm SEM of three independent experiments. (C)

5 Phase contrast and epifluorescence microphotographs of OdDHL-induced PAO-JP2 cells containing the mini-Tn5-based reporter system. The OdDHL concentrations used were: (I) 10 nM, (II) 100 nM, and (III) 1000 nM.

Fig. 3. Inhibition of quorum sensing by furanone 56. (A) Molecular structure of furanone 56 (MW: 175 g/mol). The asterisk indicates position 3 on the furanone ring. (B) Response of PAO-JP2 mini-Tn5-*PlasB-gfp(ASV) Plac-lasR* to OdDHL and furanone 56. The fluorescence signal has been normalized to 100% for 100 nM OdDHL and 0 μ g/ml furanone 56. (C) Induction of the mini-Tn5-based *PlasB-gfp(ASV)* reporter in wild type *P. aeruginosa* PAO1 in the presence of:

10 (●) 0 μ g/ml furanone 56, (σ) 5 μ g/ml furanone 56, (V) 10 μ g/ml furanone 56. (■) PAO1 with the pMH391 vector control. (D) Growth of *P. aeruginosa* PAO1 in the presence of furanone 56. Symbols as in (C).

Fig. 4. *P. aeruginosa* PAO-JP2 virulence factor production in the presence of OdDHL and furanone 56. (A) Elastase activity. (B) Chitinase activity.

20

Fig. 5. Inhibition of OdDHL-mediated signalling in *P. aeruginosa* biofilm. Twenty-four hours old biofilms of *P. aeruginosa* PAO-JP2 carrying the mini-Tn5-based *PlasB-gfp(ASV) Plac-lasR* reporter were established in flowcells. The medium was switched to contain: (I) 40 nM OdDHL, (II) 40 nM OdDHL and 2 μ g/ml furanone 56, and (III) 80 nM OdDHL and 2 μ g/ml furanone 56. Prior to the switch (0 h), the microscope was programmed to track selected microcolonies. Reflection and epifluorescence images were recorded by CSLM during the 8 hours on-line experiment. The scalebar is 20 μ m.

25

Fig. 6. Cell-density dependent activation of the *PlasB-gfp(ASV)* reporter in *P. aeruginosa* PAO1 biofilm. Green fluorescence indicates active transcription of the quorum sensing controlled *lasB* gene. The bacteria constitutively express Rfp to visualize the biomass at the substratum (right panel). Simulated fluorescence projections generated by CSLM after (I) 12 h and (II) 48 h post-inoculation. The scalebar is 20 μ m.

30

35

Fig. 7. Effect of furanone 56 on wild type *P. aeruginosa* quorum sensing and biofilm formation. *P. aeruginosa* PAO1 carrying the *lasB*-based reporter and a *dsred* expression cassette on mini-Tn5 transposons was cultivated in flowcells in the absence or presence of 5 µg/ml furanone 56. In the simulated fluorescence projections generated by CSLM, green fluorescence indicates active transcription of the quorum sensing controlled *lasB* promoter. Red fluorescence arises from constitutive expression of the *dsred* gene and, therefore, correlates to bacterial biomass accumulation at the substratum. Single cells may emit both green and red fluorescence but, for clarity, the colours are shown in separate images. The lower images provide sagittal views to visualize biofilm structure and thickness (day 7). The scalebar is 20 µm.

Fig. 8. Effect of furanone 56 on the *V. fischeri lux* quorum sensing system in *P. aeruginosa* background. The plasmid pJBA132Gm carrying the *luxR luxI-gfp*(ASV) reporter (Andersen *et al.*, 2001) was transferred to PAO-JP2. The resulting strain, PAO-JP2(pJBA312Gm), was grown in flowcells and studied by CSLM. A 24 hours old, non-fluorescent biofilm (A) was exposed to 250 nM OHHL. Within one hour biofilm bacteria became green fluorescent (B). The medium was then further modified to contain 250 nM OHHL and 15 µg/ml furanone 56. After an additional 2 hours, biofilm bacteria were significantly less green fluorescent (C). Six hours following the introduction of furanone 56, green fluorescence had almost completely disappeared (D). The scalebar is 20 µm.

DETAILED DESCRIPTION

In order that the nature of the present invention may be more clearly understood preferred forms thereof will now be described with reference to the following non-limiting examples.

Materials and Methods

Bacterial Strains. *Escherichia coli* and *P. aeruginosa* strains used in this study are listed in Table 2.

Media. The basic medium was either modified Luria-Bertani (LB) medium (Bertani, 1951) containing 4 g/liter of NaCl or ABt minimal medium (AB minimal medium (Clark & Maaløe, 1967) containing 2.5 mg/liter of thiamine).

- 5 Antimicrobial agents were added as appropriate at the following concentrations: Gentamycin, 15 µg/ml for *E. coli* and 60 µg/ml for *P. aeruginosa*; ampicillin, 100 µg/ml for *E. coli*; carbenicillin, 300 µg/ml for *P. aeruginosa*; tetracycline, 60 µg/ml for *P. aeruginosa*.

- 10 **Plasmids and DNA manipulations.** The plasmids used in this study are listed in Table 2. DNA treatment with modifying enzymes and restriction endonucleases (GibcoBRL Life Technologies, Rockville, Maryland, USA), ligation of DNA fragments with T4 ligase (GibcoBRL Life Technologies, Rockville, Maryland, USA), and transformation of *E. coli* were performed using
15 standard methods (Sambrook *et al.*, 1989). Plasmid DNA was isolated with a Spin Miniprep kit (Qiagen, Hilden, Germany) and DNA fragments were excised and purified from agarose gels using GFX DNA and Gel Band Purification kit (Amersham Pharmacia Biotech, Piscataway, New Jersey). Polymerase chain reaction was carried out on a Biometra T3 thermocycler using Expand High
20 Fidelity PCR kit (Boehringer Mannheim, Germany). Transformation of *P. aeruginosa* was performed accordingly to a previously described method (Diver *et al.*, 1990).

- The transcriptional fusion vector pMH391 was constructed by inserting the
25 1765-bp *NotI* fragment containing the RBSII-*gfp*(ASV)-T0-T1 cassette of pJBA25 (J. B. Andersen, unpublished) into *NotI*-digested pUCP22Not.

- A translational fusion between the NH-terminal part of *lasB* and an unstable variant of the *gfp* gene was constructed. The first codon of the *lasB* gene was maintained and fused to the *gfp*(ASV) open reading frame devoid of the start
30 codon (Andersen *et al.*, 1998). The fusion retains the *lasB* promoter and the 5' untranslated region of the *lasB* transcript and ensures that the native RBS and the spacing to the start codon is preserved and, therefore, that the activity of the reporter gene fusion closely reflects the expression of the *lasB* gene. The quorum sensing reporter system, pMHLAS, was constructed by a two-step
35 cloning procedure. The *PlasB-gfp*(ASV) translational fusion was made by amplifying a 348-bp PCR product starting 345-bp upstream of the *lasB* initiation

codon, using the primers *lasB* fwd and *lasB* rev and chromosomal DNA of *P. aeruginosa* PAO1 as template. The PCR-fragment was subsequently digested with *Xba*I and *Sph*I and inserted into the corresponding site of pMH391. This gave rise to the plasmid pMHLB, which carries the translational *PlasB-gfp*(ASV) followed by translational stop codons in all three reading frames and two strong transcriptional terminators (Andersen *et al.*, 1998).

In order to enhance the sensitivity of the quorum sensing monitor, the *lasR* gene under control of the *lac* promoter was inserted upstream of the *PlasB-gfp*(ASV). The *lac* promoter was chosen to drive *lasR* expression since previous studies have demonstrated that *lasR* under its own promoter was insufficient to activate the *lasB* promoter in the presence of OdDHL (Pearson *et al.*, 1995). The presence of *lasR* on the monitor plasmid allows use of very sensitive *E. coli*-based monitor strains harboring the construct in high copy-numbers. A 1002-bp *Bam*HI fragment containing the *Plac-lasR* expression cassette was generated by PCR amplification with the primer set *lasR* fwd and *lasR* rev and with pKDT17 as template. The fragment was inserted into the unique *Bam*HI site of pMHLB. The resulting plasmid, pMHLAS, contained divergent transcribed *Plac-lasR* and *PlasB-gfp*(ASV) fusions on a 3126-bp fragment flanked by *Not*I restriction sites.

The *Not*I cassette was excised from pMHLAS and inserted into the unique *Not*I site of the pTn5-Gm vector to create pTn5-LAS.

The *araC-P_{BAD}* controlled *gfp*(ASV)-expression vector was constructed by PCR amplification of a 1658-bp fragment containing the *araC-P_{BAD}* region using the primers *araCP* fwd and *araCP* rev and pBAD18 as template. The *araC-P_{BAD}* fragment was digested using the restriction endonucleases *Bcl*I and *Xba*I and was then ligated into the *Bam*HI-*Xba*I site of pMH391 giving rise to pBADGfp. The *araC-P_{BAD}-gfp*(ASV) cassette was subsequently excised as a *Not*I fragment and moved into the corresponding site of pTn5-Gm to give pTn5-BADGfp.

The plasmid used to provide a red fluorescent color-tag on bacteria was constructed as follows. pDsRed was digested with *Not*I, polished with T4 DNA Polymerase, and digested with *Pvu*II. A 916 bp blunt-ended fragment

containing the *dsred* gene under the *lac* promoter was isolated and inserted into the blunt-ended *EcoRI-HindIII* site of pMH391. This resulted in pMH210 with *Plac-dsred* followed by translational stop codons in all three reading frames and two strong transcriptional terminators. The *dsred*-expression cassette was excised as a 1916 bp *NotI*-fragment and moved into the
5 corresponding site of the pUTTc delivery vector to yield pTn5-Red. The *lac* promoter of *E. coli* acts as a constitutive promoter in *Pseudomonas* spp. due to the absence of *lac* repressor activity (Andersen *et al.*, 1998).

10 The reporter cassettes were inserted at random positions in the chromosomes of *P. aeruginosa* PAO1 and PAO-JP2 by triparental mating. The selected transconjugants with random insertion of the mini-Tn5 elements showed no sign of phenotypic changes compared to the parental strains, when tested in liquid medium or flow-chamber biofilms.

15

AHL and furanone bioassay. Strains were grown exponentially in LB or ABt medium supplemented with 0.5% glucose at 30°C, shaking at 250 rpm. At an optical density of approximately 0.8, the cultures were diluted and split into subcultures in glass culture flasks. AHLs and furanone 56 were added to
20 appropriate concentrations and the cultures were further incubated at 30°C under vigorous shaking. Culture samples were retrieved at various time intervals, and green fluorescence was measured with a fluorometer (model RF-1501, Shimadzu, Tokyo, Japan) set at an excitation wavelength of 475 nm and emission wavelength of 515 nm. Relative fluorescence was calculated as green
25 fluorescence normalized to 1 ml culture divided by the optical density (OD₆₀₀ nm).

***P. aeruginosa* biofilms.** Biofilms were grown at 30°C in three-channel flow cells (Christensen *et al.*, 1999) with individual channel dimensions of 0.3×4×40
30 mm supplied with ABt minimal medium supplemented with 2% LB. The flow system was assembled and prepared as described by Christensen *et al.* (1999). The substratum consisted of a microscope glass coverslip (Knittel 24×50 mm st1; Knittel Gläser, Braunschweig, Germany). Cultures for inoculation of the flow channels were prepared in the following way: *P.*
35 *aeruginosa* strains were streaked on LB plates with the appropriate antibiotics and incubated for 24 h at 37°C. From each plate a single colony was used for

inoculation of 10 ml ABt with 10% LB. The cultures were grown at 30°C for 18 h before they were diluted to an OD_{600 nm} of 0.1 in sterile 0.9% NaCl and used for inoculation of the flow channels. Medium flow was kept at a constant rate of 3 mL/h, equivalent to a mean flow velocity of 0.7 mm/s, using a Watson-Marlow
5 205S peristaltic pump (Watson-Marlow, Falmouth, England). Biofilms were grown for 24 hours before being shifted to media containing AHL and furanone.

Measurements of virulence factors. PAO-JP2 was grown in LB medium at 37°C and shaking at 250 rpm to an OD_{600 nm} of 1.0. The culture was divided into
10 seven subcultures, which were added 0, 70, or 1000 nM OdDHL and 0, 3, or 5 µg/ml furanone 56. The cultures were grown for an additional 4 hours at 37°C. The proteolytic activity was measured as described by Ayora & Götz (1994). Azocasein (250 µl 2%, Sigma, St. Louis, Mo.) in 50 mM Tris/HCl and steril-filtered (Ø 0.2 µm) supernatant (150 µl) were incubated for 4 h at 4°C. After
15 precipitation of undigested substrate with trichloroacetic acid (1.2 ml 10%) for 15 minutes, followed by 10 minutes centrifugation at 10000 rpm, NaOH (1.4 ml 1 M) were added to the supernatant. The relative protease activity was measured as the absorbance at 440 nm (OD_{440 nm}) of the supernatant divided by the optical density of the culture (OD_{600 nm}).

20 The chitinase activity assay was performed as described by the assay manufacturer (Loewe Biochemica, Sauerlach, Germany). Supernatant (560 µl) of cultures prepared as described for the elastase assay was mixed with carboxymethyl-chitin-remazol brilliant violet (200 µl) and sodium phosphate
25 buffer (40 µl, 1 M, pH 7.5). The reaction mixture was incubated for 18 h at 40°C in a waterbath. The reaction was stopped by addition of HCl (200 µl, 2 N) and kept for 15 min on ice. After centrifugation (10 min at 15000 rpm), the absorbance (OD_{550 nm}) of the supernatant was measured. The relative chitinase activity was calculated as OD_{550 nm}/OD_{600 nm} normalized to 1 ml supernatant.

30 **Scanning confocal laser microscopy (SCLM).** Microscopic inspection and image acquisition were performed on a scanning confocal laser microscope (model TCS4D, Leica Lasertechnik GmbH, Heidelberg, Germany) equipped with a 63×/1.32-0.6 oil objective. The microscope was equipped with a
35 motorized and programmable xy-stage, which was used for monitoring single colonies during the biofilm experiments. At the beginning of each online

experiment, the microscope was programmed to track single randomly selected microcolonies; the sensitivity of photo multipliers and the laser intensity were adjusted and thereafter kept constant through out the duration of the experiments. Image scanning was carried out using the 488 nm and 568 nm lines of an Ar/Kr laser for detection of Gfp and Rfp, respectively. Visualization of captured images was performed using the IMARIS software package (Bitplane AG, Zürich, Switzerland) running on a Silicon Graphics Indigo 2 workstation (Silicon Graphics, Mountain View, California, USA).

10 Results

Construction and characterization of *lasB*-based AHL monitor. Our genetic construct for detection of AHL signal molecules relies on the availability of a promoter, which is transcriptionally controlled by an AHL-activated LuxR-type receptor protein. Several target genes of the *las* and *rhl* quorum sensing systems of *P. aeruginosa* have been identified (Ochsner & Reiser, 1995; Passador *et al.*, 1993; Pearson *et al.*, 1997; Whiteley *et al.*, 1999; Winson *et al.*, 1995). For the purpose of OdDHL detection, we have chosen the well-characterized and tightly regulated *lasB* promoter. Several regulatory elements of the *lasB* promoter such as putative regulatory sequences have been described (Anderson *et al.*, 1999; Fukushima *et al.*, 1997; Gray *et al.*, 1994; Rust *et al.*, 1996). Previous studies using a *PlasB-lacZ* transcriptional fusion in *E. coli* MG4 have demonstrated a 63-fold induction of the promoter in response to OdDHL addition (Gray *et al.*, 1994).

We have constructed a reporter system consisting of a translational fusion of the *lasB* promoter to a gene encoding a unstable variant of Gfp, Gfp(ASV) (Andersen *et al.*, 1998). Expression of the reporter is controlled by LasR from *P. aeruginosa* in conjunction with OdDHL. Several plasmid-based systems which feature high as well as low copy numbers have been used to accommodate the present reporter cassette in *P. aeruginosa*. These include pUCP-series of *Pseudomonas*-shuttle cloning vectors (Bloemberg *et al.*, 1997; West *et al.*, 1994), the segregationally stable pME6030-based vectors (Heeb *et al.*, 2000), and mini-Tn5 transposon systems for chromosomal integration (de Lorenzo *et al.*, 1990). The copy number of each system in *P. aeruginosa* is 10,

2-4 , and 1, respectively (de Lorenzo *et al.*, 1990; Heeb *et al.*, 2000; Schweizer, 1991).

Initially, the *lasB-gfp*(ASV) translational fusion (OdDHL sensor) was thoroughly
5 characterized with respect to its sensitivity and specificity. A culture of *E. coli*
hosting the pMHLAS monitor plasmid was diluted and split into several
subcultures which were then supplemented with AHLs at concentrations
ranging from 0 to 1000 nM. Not surprisingly, the most efficient inducer of the
monitor was OdDHL, the cognate signal molecule of the *las* quorum sensing
10 system. A closely related analog, ODHL (3-oxo-C10-HSL), also activated *lasB*-
expression albeit at a lower level. The remaining AHL compounds did not
induce significant expression of the reporter gene at a concentration of 1 μ M
(Fig. 2a). When the pMHLAS based reporter system was hosted by PAO-JP2,
the OdDHL concentration required for half-maximal activation of the *lasB*-
15 *gfp*(ASV) fusion was 8 nM (data not shown). In single copy on the chromosome
of PAO-JP2, the OdDHL concentration required for half-maximal activation of
lasB expression was approximately 250 nM (Fig. 2b). Green fluorescent cells
were visible by epifluorescence microscopy at a minimal OdDHL concentration
of 50 nM (Fig. 2c).

20

Furanone-mediated inhibition of quorum sensing. Furanone compounds
produced by the Australian macroalga *D. pulchra* have been shown to possess
quorum sensing inhibitory (QSI) properties as well as interfering with complex
surface-dependent phenomena such as swarming motility and biofilm
25 formation of *Serratia liquefaciens* (Givskov *et al.*, 1996; Lindum *et al.*, 1998;
Manefield *et al.*, 1999; Manefield *et al.*, 2000). Natural furanone compounds
have a rather limited effect on *P. aeruginosa* (data not shown). However,
natural QSI compounds can be further modified by means of combinatorial
chemistry which is a highly efficient method to generate a large number of
30 analogues for screening purposes. One such synthetic furanone compound,
termed furanone 56, is characterized by a lack of side chain at the position 3 on
the furanone ring. This compound only contains one bromine substitution at the
methylene group and no bromine substitution on the furanone ring (Fig. 3a).

35 To investigate whether the furanone compound efficiently inhibited the *las*
quorum sensing system, planktonic cultures of PAO-JP2 cells harboring the

PlasB-gfp(ASV) reporter were subjected to a range of furanone 56 and OdDHL concentrations. At a concentration of 1.25 µg/ml (7.1 µM) furanone 56 inhibited *lasB-gfp*(ASV) expression at a wide range of OdDHL concentrations (Fig. 3b). In the presence of 100 nM OdDHL about 2 µg/ml (11.4 µM) furanone 56 was
5 required to reduce fluorescence by more than 50%. However, complete inhibition was not attained at any of the tested concentrations. Noteworthy, the inhibitory effect of furanone 56 was relieved at increased concentrations of OdDHL. These results clearly demonstrate that *lasB-gfp*(ASV) expression is stimulated by OdDHL, while furanone 56 antagonizes this activation.

10

The *PlasB-gfp*(ASV) reporter was inserted into the chromosome of wild type *P. aeruginosa*. Expression of *lasB-gfp*(ASV) expression was followed along the growth curve in the presence of furanone 56. Fig. 3c shows that *lasB-gfp*(ASV) expression was induced in a cell density-dependent manner. The quorum size
15 for *lasB-gfp*(ASV) induction corresponded to a cell density slightly above OD_{600 nm} of 1.0, which is in agreement with other reports (Brumlik & Storey, 1992). The data show that 5 µg/ml (28.5 µM) furanone caused a 40% reduction in *lasB-gfp*(ASV) expression in wild type *P. aeruginosa*; 10 µg/ml furanone caused a 60% reduction.

20

To determine if the furanone compound worked specifically on the *las* quorum sensor and not indirectly by disruption of primary metabolic functions, we followed growth as optical density of *P. aeruginosa* PAO1 in the presence of furanone 56. Fig. 3d shows that the furanone in concentrations used for this
25 study had no or only little effect on growth. A similar assay with *P. aeruginosa* PAO-JP2 showed no effect on growth rate (data not shown). Further, we tested whether the furanone affected *P. aeruginosa* protein synthesis. The wild type *P. aeruginosa* PAO1 strain containing the constitutive Gfp-expression vector pMH306 was grown in the presence of furanone 56 at concentrations from 0 to
30 10 µg/ml. Gfp-expression (fluorescence/ OD_{600 nm}) was throughout the growth cycle unaffected by the presence of furanone compound (data not shown).

Effect of the furanone in a heterologous background. The direct regulation exerted by the *las* regulon on *lasB* expression is well described by numerous
35 studies (Gambello & Iglewski, 1991; Pearson *et al.*, 1994; Pearson *et al.*, 1997). Regulatory complexity is added by the observation that the *las* quorum

sensing circuit itself is subject to global regulators (Albus *et al.*, 1997; Whiteley *et al.*, 2000) and that *lasB* expression is also controlled by other regulators than LasR (Brumlik & Storey, 1992; Pesci *et al.*, 1999; Schlichtman *et al.*, 1995). It was, therefore, important to rule out that QSI effect observed is not caused by

5 furanone interaction with higher levels of control. Since there is no AHL-based quorum sensing system present in *Escherichia coli* (Williams *et al.*, 2000), this bacterium provides an unbiased and well-defined genetic background for studying the direct effects of the furanone on the *P. aeruginosa las* quorum sensing system. We repeated the above-described experiments using *E. coli*

10 MT102 as a heterologous host for the reporter system. The QSI activity of the furanone was observed in this background as well (data not shown). The *E. coli* strain harboring the *lasB* reporter showed increased responsiveness to OdDHL (approx. 10-fold, see Fig. 2). This is likely to be attributed to the increased copy number of the reporter plasmid. The furanone had no effect on growth of *E. coli*

15 MT102 (data not shown).

Effect of furanone 56 on virulence factor production. The data presented above utilize a translational reporter fusion to the *lasB* promoter to study the effect of OdDHL and furanone 56. An obvious limitation to this approach is the

20 restriction of analysis to the level of transcription. We therefore investigated the effect of the furanone directly on production of the qsc virulence factors elastase and chitinase (Passador *et al.*, 1993; Winson *et al.*, 1995). Fig. 4 demonstrates that 70 nM OdDHL induced elastase and chitinase activity in *P. aeruginosa* PAO-JP2. Addition of 3 µg/ml and 5 µg/ml furanone 56 leads to a

25 reduction of elastase and chitinase activity close to the uninduced level. The activity is entirely restored by the addition of 1 µM OdDHL.

Inhibition of AHL-mediated signaling in *P. aeruginosa* biofilms. The *lasB-gfp*(ASV) reporter was integrated into the chromosome of PAO-JP2 to ensure

30 stable segregation and a constant gene dosage of the reporter system. The strain was grown in flowcells for 24 hours in ABt-LB medium and a 10-15 µm thick biofilm developed. The media flow was subsequently switched to ABt-LB medium containing the appropriate AHL and furanone concentrations. The development of green fluorescence was monitored online by CSLM for 8 hours.

35 Fig. 5 shows that the microcolonies were non-fluorescent prior to switch of media. When switched to medium containing 40 nM OdDHL, expression of the

lasB-gfp(ASV) reporter fusion was induced and visible in the single cells within four hours. Switching to a medium containing 40 nM OdDHL and 2 µg/ml furanone 56 did not lead to induction of green fluorescence in the time course of the experiment. However, green fluorescence was induced by 80 nM OdDHL and 2 µg/ml furanone 56. Induction of green fluorescence was abolished in medium contained 80 nM OdDHL and 4 µg/ml furanone (data not shown) but was observed in the presence of 150 nM OdDHL and 4 µg/ml furanone. No green fluorescence was observed in the presence of 4 µg/ml alone (data not shown).

10

To determine if the furanone-mediated inhibition of green fluorescence is due to subtle non-specific effects on protein synthesis when the bacteria are growing in a biofilm, we examined expression of green fluorescence in cells harboring the *araC-P_{BAD}-gfp*(ASV) cassette induced by suboptimal levels of L-arabinose (0.2%). The cells became green fluorescent within 2 hours after induction. The presence of furanone 56 at concentrations below 10 µg/ml had no effect on Gfp-expression (data not shown).

15

Furanone 56 represses *lasB*-expression in wild type *P. aeruginosa* biofilms. Wild type *P. aeruginosa* (PAO1) carrying a chromosomally integrated *lasB-gfp*(ASV) reporter system was grown in flowcells similar to the PAO-JP2-based reporter strain. We focused on studying the effect of furanone 56 in long-term biofilm experiments. In favor of this approach is the observation by Davies *et al.* (1998) that quorum sensing is involved in maturation of *P. aeruginosa* biofilms (up to 2 weeks old). In order to support such long-term cultivation, the biofilm medium was modified to contain 0.3 mM glucose instead of 2% LB as a carbon source. In addition, the recently available Red Fluorescent Protein (Rfp) derived from the Indopacific sea anemone *Discosoma* was employed to provide a red fluorescent tag on the biofilm bacteria. A mini-Tn5 transposon with the *dsred* gene under control of the strong constitutive *lac* promoter was inserted into the chromosome of PAO1 containing the *lasB* reporter system.

20

25

30

The dual-labeled PAO1 strain was inoculated and grown in flowcells in the absence and presence of 5 µg/ml furanone 56. The flowcells were inspected daily for ten days and scanning confocal photomicrographs were captured (Fig. 6 & 7). For clarity, the green and red fluorescent signals from the same area of

35

the biofilm are shown separately. Because the cells constitutively express Rfp, the red color correlates with cell mass, whereas the green fluorescence indicates active transcription of the *lasB-gfp*(ASV) reporter gene in response to on-going bacterial communication. We observed that the *lasB*-reporter in *P. aeruginosa* PAO1 was activated in a cell-density dependent manner as small microcolonies did not fluoresce green in contrast to larger microcolonies, which were bright green fluorescent (Fig. 6).

As evident from Fig. 7, early biofilm formation (day 1) is not or only slightly affected by the furanone, though bacterial signaling appeared to be greatly reduced. By day 7, the untreated biofilm had grown to an average thickness of $61 \pm 6 \mu\text{m}$ and bright green fluorescence was emitted by the cells. In contrast, the furanone-treated biofilm was $23 \pm 4 \mu\text{m}$ thick and cells were far less green fluorescent. Complete inhibition of the *lasB-gfp*(ASV) reporter in all biofilm bacteria by addition of furanone in concentrations, which had no effect growth ($<10 \mu\text{g/ml}$ furanone 56), was not achievable.

Repression of LuxR-activated quorum sensing controlled gene transcription. We speculated that the AHL-antagonistic properties of furanone 56 was specific to the *P. aeruginosa las* quorum sensing system. To test this, a previously published quorum sensing reporter based on the *Vibrio fischeri luxR* gene and *PluxI-gfp*(ASV) (Andersen *et al.*, 2001; Wu *et al.*, 2000) was transferred to PAO-JP2. Biofilms of PAO-JP2, grown as described above, were exposed to 250 nM OHHL (*N*-[3-oxo-hexanoyl]-L-homoserine lactone) and green fluorescence developed within one hour. Green fluorescence decreased significantly within two hours and completely disappeared after 7 hours when 15 $\mu\text{g/ml}$ furanone 56 was supplied in the medium flow (Fig. 8).

30 Discussion

Quorum sensing controlled (qsc) gene expression, i.e. cell-density dependent gene regulation, has been shown to be a common phenomenon in many Gram-negative bacteria (Fuqua & Greenberg, 1999; Greenberg, 1997; Parsek & Greenberg, 2000). In most known cases, quorum sensing systems control expression of virulence factors and hydrolytic enzymes (for recent reviews see

Eberl, 1999; Kievit & Iglewski, 2000); More complex phenotypes are also known to be quorum sensing controlled, including swarming motility of *S. liquefaciens* which is a specialized, flagella-driven movement by which a bacterial community can, in the presence of extracellular biosurfactant, spread
5 as a biofilm over a surface (Eberl *et al.*, 1996; Eberl *et al.*, 1999; Givskov *et al.*, 1997; Givskov *et al.*, 1998; Rasmussen *et al.*, 2000). Evidence is accumulating that the ability to form surface-associated, structured and co-operative consortia (referred to as biofilms) in many organisms may involve quorum sensing regulation (Costerton *et al.*, 1999; Davies *et al.*, 1998; Eberl *et al.*,
10 1999). *P. aeruginosa* has become one of the important model organisms for research in this field. This opportunistic pathogen produces a battery of extracellular virulence factors. The quorum sensing circuits of *P. aeruginosa* have been demonstrated to exert positive transcriptional control on the majority of genes encoding virulence factors, e.g. *lasB* (elastase), *lasA* (staphylytic
15 protease), *toxA* (exotoxin A), and *aprA* (alkaline protease) (Brint & Ohman, 1995; Gambello *et al.*, 1993; Gambello & Iglewski, 1991; Ochsner & Reiser, 1995; Pearson *et al.*, 1995; Seed *et al.*, 1995; Toder *et al.*, 1991). Recent studies estimated that 1-4% of the *P. aeruginosa* genes are subject to quorum sensing control (Whiteley *et al.*, 1999) and, thereby, support the view that
20 quorum sensors are involved in global control of gene expression.

P. aeruginosa has been shown to form organized, surface-attached microbial communities, called biofilms. This trait has been linked to pathogenicity of the organism in relation to pulmonary infections in cystic fibrosis (Hoiby & Koch,
25 1990; Koch & Hoiby, 1993; Pedersen *et al.*, 1992). The biofilm mode of growth seems to provide the ideal scenario for AHL-mediated quorum sensing. In contrast to the planktonic mode of growth, where signal molecules are likely to become diluted in the medium and carried away by flow, biofilms offer a diffusion-limited environment, which may allow the signal compounds to reach
30 the critical threshold concentration (Charlton *et al.*, 2000). A recent study linked quorum sensing and biofilm development by demonstrating that a *lasI* mutant is incapable of forming a highly structured wild type-like biofilm (Davies *et al.*, 1998). This observation emphasizes the need for studying quorum sensing in *P. aeruginosa* at the community level and investigating the interplay between
35 bacterial communication, biofilm mode of growth, and pathogenesis.

Clinical studies have shown that the development of resistance to antibiotics in *P. aeruginosa* is a serious side-effect of the current anti-pseudomonal treatment (Ciofu *et al.*, 1994). This has encouraged us to engage in the development of novel non-antibiotic, anti-bacterial therapies based on QSI compounds that specifically block bacterial signaling systems. In contrast to the traditional anti-microbial agents, QSI compounds work at concentrations that are well below the minimal inhibitory concentration. This concept is attractive, since such compounds will not create a selection pressure for development of resistance. Furthermore, bacteria that are insensitive to the QSI compounds because of mutations in the LuxR-type receptor proteins are expected to be unable to signal each other and therefore unable to coordinate their effort. Finally, since the selected QSI's are non-toxic for bacteria at the concentrations used they are not expected to exhibit adverse effects on beneficial bacterial consortia present in the host (for example the gut flora).

In this study we have developed novel molecular tools, which allow *in situ* detection of *N*-acyl-homoserine lactone-mediated quorum sensing and quorum sensing inhibition in *P. aeruginosa* biofilms. Our monitor system relies on a reporter gene fusion to a *qsc* promoter from *P. aeruginosa*. We have chosen the well characterized *lasB* promoter (Bever & Iglewski, 1988; Fukushima *et al.*, 1997; Gambello & Iglewski, 1991; Rust *et al.*, 1996; Toder *et al.*, 1994) and used a translational reporter fusion that retains the 5' untranslated region of the *lasB* transcript, the native RBS, and spacing to the translational start. This might be important as the 5' untranslated *lasB* mRNA is involved in post-transcriptional iron control of elastase expression (Brumlik & Storey, 1992; Brumlik & Storey, 1998). A unstable variant of Gfp (Andersen *et al.*, 1998; Andersen *et al.*, 2001) has been used as reporter. This protein is an optimal bacterial reporter for non-invasive, real-time studies of gene expression at the single cell level because no exogenous substrates and cofactors are required, except for trace amounts of oxygen for maturation, and Gfp normally does not interfere with growth of the host (Chalfie *et al.*, 1994). Notably, the unstable Gfp variant allows detection of transient bacterial communication.

The present quorum sensing reporter is highly sensitive, even when present as a single chromosomal copy, and detects OdDHL at concentrations as low as 20 nM (data not shown). In agreement with the study of Passador *et al.* (1996), we

found that OdDHL was most efficient in stimulating *lasB* promoter activity whereas ODHL and OOHL were less efficient (Fig. 2). None of the other AHL compounds tested resulted in detectable expression of the reporter gene fusion. The concentration of OdDHL needed for half-maximal activation of the *lasB* promoter was ≈ 250 nM, i.e. about one-twentieth of that found in stationary phase culture fluids of PAO1. Pearson *et al.* (1995) reported that 1 μ M OdDHL was required for half-maximal activation of a similar construct. However, our estimate is based on a reporter system in a single chromosomal copy in PAO-JP2 whereas the former study used a plasmid-based reporter (pKDT17) in a *P. aeruginosa rhIR* mutant (PAO-R1). The differences in copy number and strain background could account for the different estimates.

We have cultivated *P. aeruginosa* strains harboring the quorum sensing reporter in laboratory-based flowcells. Using SCLM, we were able to monitor of quorum sensing *in situ* at the single-cell level in biofilms. In the present report, we did not perform a detailed study on the induction of the reporter system in wild type biofilms in relation to microcolony quorum size or threshold OdDHL concentration. However, we did observe that the size of the microcolonies did correlate with induction of the *lasB*-reporter fusion as would be expected (Fig. 6). In PAO-JP2 biofilms, *lasB* promoter activity could be induced by OdDHL in concentrations as low as 20 nM.

Furanone compounds produced by *D. pulchra* have previously been demonstrated to specifically interfere with several AHL-regulated bacterial processes without any effect on bacterial growth or general protein synthesis capability (Givskov *et al.*, 1996; Manefield *et al.*, 2000). The current hypothesis is that the furanone compounds antagonize AHLs by competition for the binding site on the receptor protein. Recently, Manefield *et al.* (1999) showed that halogenated furanones, at the concentrations produced by the alga, are capable of displacing OHHL molecules from the cognate LuxR receptor protein.

In this study we have employed a novel synthetic furanone, which displays enhanced AHL-antagonistic properties and has no or little effect on growth of *P. aeruginosa*. Quantitative data from planktonic cultures showed that furanone 56 caused a significant reduction in OdDHL-activated expression of a *lasB-gfp*(ASV) reporter in *P. aeruginosa*. The interference by the furanone 56 occurs

in a competitive fashion, though the stoichiometric furanone-to-OdDHL ratio is approximately 400:1. This ratio is in good agreement to study by Kline *et al.* (1999) using structural analogs of OdDHL as possible agonists and antagonists of OdDHL. The disproportionate ratio probably reflects the well-documented high affinity of LasR for OdDHL (Gray *et al.*, 1994; Passador *et al.*, 1996). This might also explain our failure to achieve complete inhibition of *lasB* expression by addition non-toxic concentrations of furanone 56. The compound repressed *lasB* promoter activity in a heterologous *E. coli* background, which is devoid of an AHL-mediated quorum sensing system. This supports the model that the algal metabolite specifically interferes with AHL-dependent gene transcription at the level of the LasR regulatory protein.

The *P. aeruginosa las* and *rhl* quorum sensing circuits are subject to additional levels of regulation. Transcription of *lasR* was shown to be positively regulated by the virulence factor regulator (Vfr) protein (Albus *et al.*, 1997) and to be subject to negative regulation by the product of the *rsaL* gene, which was recently identified downstream of *lasR* (de Kievit *et al.*, 1999). Production of BHL was shown to be reduced in a *P. aeruginosa gacA* mutant and a model has been proposed that places GacA upstream of LasR and RhIR (Reimann *et al.*, 1997). Moreover, recent results suggest that the *rhl* system is controlled by RpoS, the sigma factor, which is required for general stress response of *P. aeruginosa* (Whiteley *et al.*, 2000). It might be speculated that the furanone interferes with one or more of these higher-level regulatory circuits. To exclude this possibility, we investigated if the furanone affects a heterologous quorum sensing system hosted by *P. aeruginosa*. The *Vibrio fischeri lux* quorum sensing system represents a distinct cell-to-cell communication system not amenable to endogenous *P. aeruginosa* regulators and might be regarded as a "clean" system in *P. aeruginosa*. In the present study, furanone 56 was observed to interfere with OHHL-LuxR activated expression of a *luxR PluxI-gfp(ASV)* fusion. This strengthens the hypothesis that the furanone antagonizes AHLs by interaction with the LuxR-type receptors. Secondly, the effect on the *luxR-PluxI-gfp(ASV)* reporter indicates that furanone 56 has a broad activity in interaction with LuxR-type receptor proteins, i.e. the particular furanone is not limited only to be an antagonist of OdDHL-LasR complex formation in *P. aeruginosa* but might also be used to interfere with AHL-mediated cell-to-cell communication in other Gram-negative bacteria.

The furanone did not have any significant effect on bacterial growth rates at concentrations below 10 µg/ml. In addition, we observed no negative, non-AHL related effects on bacterial protein synthesis when Gfp-expression under control of the *araBAD* promoter was induced by suboptimal levels of L-arabinose. The data are in agreement with previous two-dimensional PAGE analysis demonstrating that furanones have no gross effect on bacterial protein synthesis (Manefield *et al.*, 1999).

- 10 The *lasB* transcription data was complemented by measurements of the production of two quorum sensing controlled virulence factors, elastase and chitinase. In PAO-JP2, OdDHL clearly stimulated elastase and chitinase activity. The activities were reduced to near uninduced levels upon addition of furanone 56. Restoration of near fully induced levels could be achieved by addition of excess amounts of OdDHL.

We have developed a novel dual-labeling methodology to study quorum sensing in wild-type *P. aeruginosa* biofilms. *P. aeruginosa* PAO1 was manipulated to contain the *lasB-gfp*(ASV) fusion as a green fluorescent reporter of quorum sensing. Additionally, the strain was equipped with a chromosomally integrated Rfp-expression cassette to provide a constitutive red fluorescent color-tag on biofilm bacteria. To our knowledge, this is the first report on utilization of the Red Fluorescent Protein in *P. aeruginosa*.

- 25 Inhibition of AHL-mediated signaling in the wild-type strain represents additional challenges: the AHL concentration can not be controlled, and the reporter system is subject to additional regulation by the *rhl* quorum sensing system, which works in conjunction to the *las* circuit to maximize *lasB* expression (Pearson *et al.*, 1995). Furthermore, the reporter system in the wild-type responds to endogenous and exogenous OdDHL, whereas the PAO-JP2-based reporter strain responds solely to incoming signal molecules. Considering the potential involvement of efflux pumps in transport of furanone compounds, this might be an important difference. Transcription of the *lasB* promoter was approximately 2-fold reduced in planktonic cultures of PAO1. In biofilms, the reporter system was partially shut down in the presence of 5 µg/ml furanone 56. It is uncertain if the relatively weak reduction of *lasB* expression

would be sufficient to render the wild-type strain significantly less virulent. However, keeping in mind that *lasB* belongs to the top of the quorum sensing cascade (Latifi *et al.*, 1996; Seed *et al.*, 1995), it is likely that qsc genes located at lower levels in the regulatory hierarchy might be more severely affected as these genes require higher OdDHL concentrations for activation. The observations by Davies *et al.* (1998) indicate the existence of qsc genes involved in late *P. aeruginosa* biofilm maturation. Our study shows that early biofilm formation, i.e. attachment to the surface, is not affected by the furanone. However, we observed that the wild type biofilm, when grown in the presence of furanone, failed to mature and showed an architecture that strongly resembled the one of the PAO1 *las* mutant observed by Davies *et al.* (1998). This leads to the hypothesis that the furanone may inhibit expression of the yet unidentified qsc gene(s) responsible for biofilm maturation.

In the present study we have demonstrated the use of furanone compounds as a QSI compounds. Furanone 56 interferes with OdDHL-dependent transcription of a *lasB-gfp*(ASV) reporter fusion, reduces extracellular elastase and chitinase activity in PAO-JP2 grown in the presence of OdDHL, and has no or little effect on bacterial growth and protein synthesis. Further, we have demonstrated that the furanone is capable of penetrating the *P. aeruginosa* biofilm matrix where it interferes with quorum sensing controlled gene expression and, as a consequence, with biofilm maturation.

Quantitative furanone inhibition of a the *luxR-PluxI-gfp*(ASV) encode quorum sensor

To analyse the AHL antagonist activity of the halogenated furanones we tested the compounds for their ability to inhibit 3-oxo-C6-HSL (OHHL) induced LuxR dependent expression of green fluorescent protein (GFP) from a *P_{luxI}-gfp*(ASV) fusion in the AHL monitor strain *E. coli* MT102 harbouring pJBA89 (Andersen *et al.*, 2001).

Method:

The medium used is minimal ABT containing 0.5% glucose and 0.5% Casamino Acids. In growing cultures of the AHL monitor strain *E. coli* MT102 (pJBA89) encoding *luxR* and a *P_{luxI}-gfp*(ASV) fusion, GFP(ASV) is produced immediately upon OHHL addition specifically from the LuxR controlled *P_{luxI}-gfp*(ASV) fusion gene. The sensitivity is high (responsive to as little as 3 nM OHHL)

and due to the instability built into the GFP (ASV) variant there is no background production of green fluorescence (Andersen *et al.*, 2001). GFP expression from the AHL monitor strain *E. coli* MT102 (pJBA89) and the control strain MT102 harbouring the *lacI^q*, *P_{lac}-gfp*(ASV) IPTG inducible expression system pMH197 was quantified in the following way. Overnight cultures were diluted four fold in fresh medium and incubated for one hour at 30 °C while OHHL and furanone compounds in the required concentrations were mixed in the wells of microtiter dishes. Next, the bacterial culture was distributed to the wells of the microtiter dish (100µl aliquots), mixed with the previously pipetted compounds and further incubated for two hours at 30 °C (see below). For measurements of GFP, the microtiter dishes were placed in a light sealed dark box (UnitOne, Birkerød, Denmark) and illuminated with a halogen lamp (Intralux 5000-1, Volpi, Switzerland) equipped with a 480/40 excitation filter (F44-001, AF Analysentechnik, Tübingen, Germany). Green fluorescent images were captured with a Hamamatsu C2400-47 double intensified CCD camera (Hamamatsu, Herrsching, Germany) using a 532/10 emission filter (Melles Griot 03 FIV111, Melles Griot, Irvine, CA). A PC computer controlled the camera and the images were saved in 16-bit format (the scale has a resolution of 16 colours) using the ARGUS-50 software (Hamamatsu). When absolute values were required, green fluorescence was measured on a fluorometer (model RF-1501; Shimadzu, Tokyo, Japan) set at an excitation wavelength of 475 nm and emission detection at 515 nm. To establish a correlation between the colour code of the ARGUS-50 captured images and green fluorescence, both colour and relative fluorescence units (RFU), were determined for a dilution series of an *E. coli* MT102 (pJBA89) culture which had been incubated with 100 OHHL. The dilution giving 14 colours and 520 RFU was defined as having 100 % RFU. Accordingly, the other colours were assigned a RFU value and a standard curve-relating colour to RFU was constructed. The best straight line was $y = 8x - 16$ where y is RFU and x the number of colours (x must be in the range 2-14 colours for reliable measurements).

| | ROW 1 | ROW 2 | ROW 3 | ROW 4 | ROW 5 |
|--------|--|---|---|---|--|
| Well A | 5nM OHHL 10 μ g/mL furanone | 10nM OHHL 10 μ g/mL furanone | 25nM OHHL 10 μ g/mL furanone | 50nM OHHL 10 μ g/mL furanone | 100nM OHHL 10 μ g/mL furanone |
| Well B | 5nM OHHL 5 μ g/mL furanone | 10nM OHHL 5 μ g/mL furanone | 25nM OHHL 5 μ g/mL furanone | 50nM OHHL 5 μ g/mL furanone | 100nM OHHL 5 μ g/mL furanone |
| Well C | 5nM OHHL 2.5 μ g/mL furanone | 10nM OHHL 2.5 μ g/mL furanone | 25nM OHHL 2.5 μ g/mL furanone | 50nM OHHL 2.5 μ g/mL furanone | 100nM OHHL 2.5 μ g/mL furanone |
| Well D | 5nM OHHL 1.25 μ g/mL furanone | 10nM OHHL 1.25 μ g/mL furanone | 25nM OHHL 1.25 μ g/mL furanone | 50nM OHHL 1.25 μ g/mL furanone | 100nM OHHL 1.25 μ g/mL furanone |
| Well E | 5nM OHHL 0.63 μ g/mL furanone | 10nM OHHL 0.63 μ g/mL furanone | 25nM OHHL 0.63 μ g/mL furanone | 50nM OHHL 0.63 μ g/mL furanone | 100nM OHHL 0.63 μ g/mL furanone |
| Well F | 5nM OHHL 0.31 μ g/mL furanone | 10nM OHHL 0.31 μ g/mL furanone | 25nM OHHL 0.31 μ g/mL furanone | 50nM OHHL 0.31 μ g/mL furanone | 100nM OHHL 0.31 μ g/mL furanone |
| Well G | 5nM OHHL 0.16 μ g/mL furanone | 10nM OHHL 0.16 μ g/mL furanone | 25nM OHHL 0.16 μ g/mL furanone | 50nM OHHL 0.16 μ g/mL furanone | 100nM OHHL 0.16 μ g/mL furanone |
| Well H | 5nM OHHL 0 μ g/mL furanone | 10nM OHHL 0 μ g/mL furanone | 25nM OHHL 0 μ g/mL furanone | 50nM OHHL 0 μ g/mL furanone | 100nM OHHL 0 μ g/mL furanone |

The relative activity in each well of the sample plate is found using the standard curve. Three plots are made, one showing relative activity as a function of OHHL concentration, one curve for each furanone concentration. The second plot is relative activity as a function of furanone concentration, one curve for each OHHL concentration. The third is a 3D plot showing relative activity as a function of both OHHL and furanone concentration.

From the second plot, the furanone concentration reducing the relative activity to 40% (ID₄₀) is determined for each OHHL concentration. Finally, a fourth plot is made showing the ID₄₀ values as a function of OHHL concentration.






Results







To enable easy comparison of the strength of the furanones, an inhibition index ($II_{X_{40}}$) is calculated for each furanone compound. Each halogenated furanone was tested at 8 different concentrations in the presence of 5 different OHHL concentrations.






- 5 The inhibitory activity of each compound on the fluorescent phenotype was diminished as the 3-oxo-C6-HSL concentration increased. All 40 fluorescence readings obtained for the compound are presented in Figure 2A (see Table 1 for structures). For each furanone tested the 40 readings were used to determine the concentration which, at each OHHL concentration, lowered the RFU value to 40 % of the untreated sample.
- 10 The five values obtained, one for each OHHL concentration, were plotted as a function of the OHHL concentration and the gradient of the best straight line passing through the origin was taken as the inhibition index ($II_{X_{40}}$). The $II_{X_{40}}$ expresses the number of mole of furanone per mmole of OHHL required to inhibit fluorescence to 40 %. A low $II_{X_{40}}$ value therefore indicates that a compound is an efficient QSI.
- 15 Interestingly, furanone 56 and 30 have the same basic structure as the classic furanones; except it lacks a R_1 side chain and a R_2/R_3 Br atom. The natural compound 2 has an $II_{X_{40}}$ 0.75 where as compound 30 and 56 have $II_{X_{40}}$ of 0.01 and 0.51 respectively. Compound 2 did not result in bacterial growth inhibition at the concentrations tested (> 50 nM) whereas 30 and 56 inhibited growth slightly above 10
- 20 and 50 nM respectively)

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be

25 considered in all respects as illustrative and not restrictive.

| Compound No. | Structure |
|--------------|---|
| 2 (d3) |  |
| 3 (d5) |  |
| 19 |  |
| 24 |  |
| 26 |  |

| Compound No. | Structure |
|--------------|---|
| 30 |  |
| 34 |  |
| 56 |  |
| 70 |  |
| 72 |  |
| 74 |  |

| Compound No. | Structure |
|--------------|--|
| 75 |  |
| 76 |  |
| 78 |  |
| 19 |  |
| 77 |  |








Table 2. Bacterial strains and plasmids used in this study

| Strains and plasmids | Relevant genotype and characteristics | Reference |
|----------------------|--|-----------------------------------|
| <i>E. coli</i> | | |
| MT102 | F ⁻ <i>thi araD139 ara-leu</i> Δ7679 Δ(<i>lacIOPZY</i>) <i>galU gal'K r⁻ m⁺ Sm^R</i> | T. Hansen, Novo Nordisk A/S |
| CC118 λpir | Δ(<i>ara-leu</i>) <i>araD</i> Δ <i>lacX74 galE galK phoA20 thi-1 rps-1 rpoB argE</i> (Amp) <i>recA thi pro hsdRM⁺</i> RP4-2-Tc::Mu-Km::Tn7 λpir | (Herrero <i>et al.</i> , 1990) |
| <i>P. aeruginosa</i> | | |
| PAO1 | Wild-type <i>P. aeruginosa</i> | (Holloway, 1955) |
| PAO-JP2 | <i>lasI rhII</i> derivative of PAO1, Hg ^R Tc ^R | (Pearson <i>et al.</i> , 1997) |
| Plasmids | | |
| pJBA25 | Ap ^R ; pUC18NotI RBSII- <i>gfp</i> (ASV)-T ₀ -T ₁ | (J. B. Andersen, unpublished) |
| pJBA132Gm | Tc ^R Gm ^R ; <i>luxR PluxI-gfp</i> (ASV) | (Andersen <i>et al.</i> , 2001) |
| pUCP22Not | Ap ^R Gm ^R ; <i>Pseudomonas</i> -shuttle and cloning vector, ori pRO1614 | (Herrero <i>et al.</i> , 1990) |
| pKDT17 | Ap ^R , <i>lasB-lacZ Plac-lasR</i> | (Pearson <i>et al.</i> , 1994) |
| pUTTc | Ap ^R Tc ^R ; Tn5-based delivery plasmid | (de Lorenzo <i>et al.</i> , 1990) |
| pTn5-Gm | Ap ^R Gm ^R ; Tn5-based delivery plasmid | (Whiteley <i>et al.</i> , 2000) |
| pDsRed | Ap ^R ; DsRed expression | CLONTECH |

| Strains and plasmids | Relevant genotype and characteristics | Reference |
|----------------------|--|--------------------------------|
| | vector | Laboratories, Inc. |
| pTn5-Red | Ap ^R Tc ^R ; pUTTc carrying <i>Plac-dsred-T₀-T₁</i> | This study |
| pMH306 | Ap ^R Gm ^R ; pUCP22Not carrying <i>P_{A1/04/03}-RBSII-gfp(ASV)-T₀-T₁</i> | This study |
| pMH391 | Ap ^R Gm ^R ; <i>Pseudomonas</i> -shuttle and <i>gfp(ASV)</i> -fusion vector with RBSII- <i>gfp(ASV)-T₀-T₁</i> | This study |
| pMHLB | Ap ^R Gm ^R ; pMH391 carrying <i>PlasB-gfp(ASV)</i> | This study |
| pMHLAS | Ap ^R Gm ^R ; pMH391 carrying <i>PlasB-gfp(ASV)</i> <i>Plac-lasR</i> | This study |
| pTn5-LAS | Ap ^R Gm ^R ; pTn5-Gm carrying <i>PlasB-gfp(ASV)</i> <i>Plac-lasR</i> | This study |
| pBAD18 | Ap ^R ; <i>araC P_{BAD}</i> promoter | (Guzman <i>et al.</i> , 1995) |
| pBADGfp | Ap ^R Gm ^R ; <i>Pseudomonas</i> -shuttle vector with <i>araC P_{BAD}-gfp(ASV)</i> | This study |
| pTn5-BADGfp | Ap ^R Gm ^R ; pTn5-Gm carrying <i>araC P_{BAD}-gfp(ASV)</i> | This study |
| pRK600 | Cm ^R ; <i>ori</i> ColE1 RK2-Mob ⁺ RK2-Tra ⁺ ; helper plasmid in triparental conjugations | (Kessler <i>et al.</i> , 1992) |
| Primers | <i>lasB</i> fwd | 5'- |

| Strains and plasmids | Relevant genotype and characteristics | Reference |
|----------------------|---------------------------------------|--|
| | | GCTCTAGAGCGGCCA GGAAAGCGTGCAA-3' |
| | lasB rev | 5'- GCTGCTGCATGCTTGT TCAGTTCTCCTGGT-3' |
| | lasR fwd | 5'- CGGGATCCGGCACGA CAGGTTTCCCGAC-3' |
| | lasR rev | 5'- GCCGGCCAGTGCCAA GCTTGC-3' |
| | araCP fwd | 5'- GGGTACGTCGACTGA TCACCTATGCTACTCC GTCAAGCCG-3' |
| | araCP rev | 5'- GCGCTCGTCGACTGA TCAGTTCAAATCCGCT CCCGGCCG-3' |
| | | |

REFERENCES

- Albus, A. M., Pesci, E. C., Runyen-Janecky, L. J., West, S. E., and Iglewski, B. H. (1997). Vfr controls quorum sensing in *Pseudomonas aeruginosa*. *J Bacteriol* **179**, 3928-3935.
- Andersen, J. B., Heydorn, A., Hentzer, M., Eberl, L., Geisenberger, O., Christensen, B. B., Molin, S., and Givskov, M. (2001). *gfp* based *N*-acyl-homoserine-lactone monitors for detection of bacterial communication. *Appl Environ Microbiol* **67**, 575-585.
- Andersen, J. B., Sternberg, C., Poulsen, L. K., Bjorn, S. P., Givskov, M., and Molin, S. (1998). New unstable variants of green fluorescent protein for studies of transient gene expression in bacteria. *Appl Environ Microbiol* **64**, 2240-2246.
- Anderson, R. M., Zimprich, C. A., and Rust, L. (1999). A Second Operator Is Involved in *Pseudomonas aeruginosa* Elastase (*lasB*) Activation. *J Bacteriol* **181**, 6264-6270.
- Ayora, S. and Gotz, F. (1994). Genetic and biochemical properties of an extracellular neutral metalloprotease from *Staphylococcus hyicus* subsp. *hyicus*. *Mol Gen Genet* **242**, 421-430.
- Bertani, G. (1951). Studies on lysogenesis. I. The mode of phage liberation by lysogenic *Escherichia coli*. *J Bacteriol* **62**, 293-300.
- Bever, R. A. and Iglewski, B. H. (1988). Molecular characterization and nucleotide sequence of the *Pseudomonas aeruginosa* elastase structural gene. *J Bacteriol* **170**, 4309-4314.
- Bloemberg, G. V., O'Toole, G. A., Lugtenberg, B. J. J., and Kolter, R. (1997). Green fluorescent protein as a marker for *Pseudomonas* spp. *Appl Environ Microbiol* **63**, 4543-4551.
- Brint, J. M. and Ohman, D. E. (1995). Synthesis of multiple exoproducts in *Pseudomonas aeruginosa* is under the control of RhIR-RhII, another set of regulators in strain PAO1 with homology to the autoinducer-responsive LuxR-LuxI family. *J Bacteriol* **177**, 7155-7163.
- Brumlik, M. J. and Storey, D. G. (1992). Zinc and iron regulate translation of the gene encoding *Pseudomonas aeruginosa* elastase. *Mol Microbiol* **6**, 337-344.

- Brumlik, M. J. and Storey, D. G. (1998).** Post-transcriptional control of *Pseudomonas aeruginosa lasB* expression involves the 5' untranslated region of the mRNA. *FEMS Microbiol Lett* **159**, 233-239.
- Chalfie, M., Tu, Y., Euskirchen, G., Ward, W. W., and Prasher, D. C. (1994).**
- 5 Green fluorescent protein as a marker for gene expression. *Science* **263**, 802-805.
- Charlton, T. S., de Nys, R., Netting, A., Kumar, N., Hentzer, M., Givskov, M., and Kjelleberg, S. (2000).** A novel and sensitive method for the quantification of *N*-3-oxo-acyl homoserine lactones using gas chromatography-mass spectrometry: application to a model bacterial biofilm. *Environmental Microbiology* **2**, 530-541.
- 10 **Christensen, B. B., Sternberg, C., Andersen, J. B., Palmer, R. J., Jr., Nielsen, A. T., Givskov, M., and Molin, S. (1999).** Molecular tools for study of biofilm physiology. *Methods Enzymol* **310**, 20-42.
- 15 **Ciofu, O., Giwercman, B., Pedersen, S. S., and Hoiby, N. (1994).** Development of antibiotic resistance in *Pseudomonas aeruginosa* during two decades of antipseudomonal treatment at the Danish CF Center. *APMIS* **102**, 674-680.
- Clark, D. J. and Maaløe, O. (1967).** DNA replication and the division cycle in
- 20 *Escherichia coli*. *J Mol Biol* **23**, 99-112.
- Costerton, J. W., Lewandowski, Z., Caldwell, D. E., Korber, D. R., and Lappin-Scott, H. M. (1995).** Microbial biofilms. *Annu Rev Microbiol* **49**, 711-745.
- Costerton, J. W., Stewart, P. S., and Greenberg, E. P. (1999).** Bacterial
- 25 biofilms: a common cause of persistent infections. *Science* **284**, 1318-1322.
- Davies, D. G., Parsek, M. R., Pearson, J. P., Iglewski, B. H., Costerton, J. W., and Greenberg, E. P. (1998).** The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* **280**, 295-298.
- de Kievit, T., Seed, P. C., Nezezon, J., Passador, L., and Iglewski, B. H.**
- 30 **(1999).** RsaL, a novel repressor of virulence gene expression in *Pseudomonas aeruginosa*. *J Bacteriol* **181**, 2175-2184.
- De Kievit, T. R. and Iglewski, B. H. (2000).** Bacterial quorum sensing in pathogenic relationships. *Infect Immun* **68**, 4839-4849.
- de Lorenzo, V., Herrero, M., Jakubzik, U., and Timmis, K. N. (1990).** Mini-
- 35 Tn5 transposon derivatives for insertion mutagenesis, promoter probing, and

- chromosomal insertion of cloned DNA in gram-negative eubacteria. *J Bacteriol* **172**, 6568-6572.
- de Nys, R., Steinberg, P. D., Willemsen, P., Dworjanyn, S. A., Gabelish, C. L., and King, R. J. (1995). Broad spectrum effects of secondary metabolites from the red alga *Delisea pulchra* in antifouling assays. *Biofouling* **8**, 259-271.
- de Nys, R., Wright, A. D., König, G. M., and Sticher, O. (1993). New halogenated furanones from the marine alga *Delisea pulchra*. *Tetrahedron* **49**, 11213-11220.
- Diver, J. M., Bryan, L. E., and Sokol, P. A. (1990). Transformation of *Pseudomonas aeruginosa* by electroporation. *Anal Biochem* **189**, 75-79.
- Eberl, L. (1999). *N*-acyl homoserinelactone-mediated gene regulation in gram-negative bacteria. *Syst Appl Microbiol* **22**, 493-506.
- Eberl, L., Molin, S., and Givskov, M. (1999). Surface Motility of *Serratia liquefaciens* MG1. *J Bacteriol* **181**, 1703-1712.
- Eberl, L., Winson, M. K., Sternberg, C., Stewart, G. S. A. B., Christiansen, G., Chhabra, S. R., Bycroft, B. W., Williams, P., Molin, S., and Givskov, M. (1996). Involvement of *N*-acyl-L-homoserine lactone autoinducers in controlling the multicellular behaviour of *Serratia liquefaciens*. *Mol Microbiol* **20**, 127-136.
- Fukushima, J., Ishiwata, T., You, Z., Ishii, T., Shigematsu, T., Kurata, M., Chikumaru-Fujita, S., Bycroft, B. W., Stewart, G. S., Kawamoto, S., Williams, P., and Okuda, K. (1997). Dissection of the promoter/operator region and evaluation of *N*-acylhomoserine lactone mediated transcriptional regulation of elastase expression in *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* **146**, 311-318.
- Fuqua, C. and Greenberg, E. P. (1999). Self perception in bacteria: quorum sensing with acylated homoserine lactones. *Curr Opin Microbiol* **1**, 183-189.
- Fuqua, C., Winans, S. C., and Greenberg, E. P. (1997). Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. *J Bacteriol* **176**, 269-275.
- Gambello, M. J. and Iglewski, B. H. (1991). Cloning and characterization of the *Pseudomonas aeruginosa lasR* gene, a transcriptional activator of elastase expression. *J Bacteriol* **173**, 3000-3009.
- Gambello, M. J., Kaye, S., and Iglewski, B. H. (1993). LasR of *Pseudomonas aeruginosa* is a transcriptional activator of the alkaline protease gene (*apr*) and an enhancer of exotoxin A expression. *Infect Immun* **61**, 1180-1184.

- Givskov, M., de Nys, R., Manefield, M., Gram, L., Maximilien, R., Eberl, L., Molin, S., Steinberg, P. D., and Kjelleberg, S. (1996). Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. *J Bacteriol* **178**, 6618-6622.
- 5 Givskov, M., Eberl, L., and Molin, S. (1997). Control of exoenzyme production, motility and cell differentiation in *Serratia liquefaciens*. *FEMS Microbiol Lett* **148**, 115-122.
- Givskov, M., Ostling, J., Eberl, L., Lindum, P. W., Christensen, A. B., Christiansen, G., Molin, S., and Kjelleberg, S. (1998). Two separate
10 regulatory systems participate in control of swarming motility of *Serratia liquefaciens* MG1. *J Bacteriol* **180**, 742-745.
- Glessner, A., Smith, R. S., Iglewski, B. H., and Robinson, J. B. (1999). Roles of *Pseudomonas aeruginosa* *las* and *rhl* Quorum-Sensing Systems in Control of Twitching Motility. *J Bacteriol* **181**, 1623-1629.
- 15 Gray, K. M., Passador, L., Iglewski, B. H., and Greenberg, E. P. (1994). Interchangeability and specificity of components from the quorum-sensing regulatory systems of *Vibrio fischeri* and *Pseudomonas aeruginosa*. *J Bacteriol* **176**, 3076-3080.
- Greenberg, E. P. (1997). Quorum sensing in gram-negative bacteria. *ASM News* **63**, 371-377.
20
- Guzman, L. M., Belin, D., Carson, M. J., and Beckwith, J. (1995). Tight regulation, modulation, and high-level expression by vectors containing the arabinose P_{BAD} promoter. *J Bacteriol* **177**, 4121-4130.
- Hassett, D. J., Ma, J. F., Elkins, J. G., McDermott, T. R., Ochsner, U. A.,
25 West, S. E., Huang, C. T., Fredericks, J., Burnett, S., Stewart, P. S., McFeters, G., Passador, L., and Iglewski, B. H. (1999). Quorum sensing in *Pseudomonas aeruginosa* controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. *Mol Microbiol* **34**, 1082-1093.
- 30 Heeb, S., Itoh, Y., Nishijyo, T., Schnider, U., Keel, C., Wade, J., Walsh, U., O'Gara, F., and Haas, D. (2000). Small, stable shuttle vectors based on the minimal pVS1 replicon for use in gram-negative, plant-associated bacteria. *Mol Plant Microbe Interact* **13**, 232-237.
- Herrero, M., de Lorenzo, V., and Timmis, K. N. (1990). Transposon vectors
35 containing non-antibiotic resistance selection markers for cloning and stable

- chromosomal insertion of foreign genes in gram-negative bacteria. *J Bacteriol* **172**, 6557-6567.
- Holby, N. (1977).** *Pseudomonas aeruginosa* infection in cystic fibrosis. Diagnostic and prognostic significance of *Pseudomonas aeruginosa* precipitins determined by means of crossed immunoelectrophoresis. A survey. *Acta Pathol Microbiol Scand Suppl* 1-96.
- Holby, N. (2000).** Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. *Paediatr Drugs* **2**, 451-463.
- Holby, N. and Koch, C. (1990).** *Pseudomonas aeruginosa* infection in cystic fibrosis and its management. *Thorax* **45**, 881-884.
- Holloway, B. W. (1955).** Genetic Recombination in *Pseudomonas aeruginosa*. *J Gen Microbiol* **13**, 572-581.
- Kessler, B., de, Lorenzo, V, and Timmis, K. N. (1992).** A general system to integrate *lacZ* fusions into the chromosomes of gram- negative eubacteria: regulation of the Pm promoter of the TOL plasmid studied with all controlling elements in monocopy. *Mol Gen Genet* **233**, 293-301.
- Kjelleberg, S., Steinberg, P. D., Givskov, M., Gram, L., Manefield, M., and de Nys, R. (1997).** Do marine natural products interfere with prokaryotic AHL regulatory systems? *Aquat Microb Ecol* **13**, 85-93.
- Kleerebezem, M., Quadri, L. E., Kuipers, O. P., and de Vos, W. M. (1997).** Quorum sensing by peptide pheromones and two-component signal-transduction systems in Gram-positive bacteria. *Mol Microbiol* **24**, 895-904.
- Kline, T., Bowman, J., Iglewski, B. H., de Kievit, T., Kakai, Y., and Passador, L. (1999).** Novel synthetic analogs of the *Pseudomonas* autoinducer. *Bioorg Med Chem Lett* **9**, 3447-3452.
- Koch, C. and Holby, N. (1993).** Pathogenesis of cystic fibrosis. *Lancet* **341**, 1065-1069.
- Lam, J., Chan, R., Lam, K., and Costerton, J. W. (1980).** Production of mucoid microcolonies by *Pseudomonas aeruginosa* within infected lungs in cystic fibrosis. *Infect Immun* **28**, 546-556.
- Latifi, A., Foglino, M., Tanaka, K., Williams, P., and Lazdunski, A. (1996).** A hierarchical quorum-sensing cascade in *Pseudomonas aeruginosa* links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS. *Mol Microbiol* **21**, 1137-1146.
- Lindum, P. W., Anthoni, U., Christophersen, C., Eberl, L., Molin, S., and Givskov, M. (1998).** *N*-Acyl-L-homoserine lactone autoinducers control

- production of an extracellular lipopeptide biosurfactant required for swarming motility of *Serratia liquefaciens* MG1. *J Bacteriol* **180**, 6384-6388.
- Manefield, M., de Nys, R., Kumar, N., Read, R., Givskov, M., Steinberg, P. D., and Kjelleberg, S. (1999).** Evidence that halogenated furanones from
- 5 *Delisea pulchra* inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. *Microbiology* **145**, 283-291.
- Manefield, M., Harris, L., Rice, S. A., de Nys, R., and Kjelleberg, S. (2000).** Inhibition of luminescence and virulence in the black tiger prawn (*Penaeus monodon*) pathogen *Vibrio harveyi* by intercellular signal antagonists. *Appl Environ Microbiol* **66**, 2079-2084.
- 10 **O'Toole, G. A. and Kolter, R. (1998).** Flagellar and twitching motility are necessary for *Pseudomonas aeruginosa* biofilm development. *Mol Microbiol* **30**, 295-304.
- 15 **Ochsner, U. A. and Reiser, J. (1995).** Autoinducer-mediated regulation of rhamnolipid biosurfactant synthesis in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* **92**, 6424-6428.
- Ohman, D. E., Cryz, S. J. Jr, and Iglewski, B. H. (1980).** Isolation and characterization of *Pseudomonas aeruginosa* PAO mutant that produces
- 20 altered elastase. *J Bacteriol* **142**, 836-842.
- Parsek, M. R. and Greenberg, E. P. (2000).** Acyl-homoserine lactone quorum sensing in gram-negative bacteria: a signalling mechanism involved in associations with higher organisms. *Proc Natl Acad Sci U S A* **97**, 8789-8793.
- Passador, L., Cook, J. M., Gambello, M. J., Rust, L., and Iglewski, B. H.**
- 25 **(1993).** Expression of *Pseudomonas aeruginosa* virulence genes requires cell-to-cell communication. *Science* **260**, 1127-1130.
- Passador, L. and Iglewski, B. H. (1995)** Quorum sensing and virulence gene regulation in *Pseudomonas aeruginosa*. In *Virulence Mechanisms of Bacterial Pathogens*, pp. 65-78. Edited by J. A. Roth. Washington, DC.: American
- 30 Society for Microbiology.
- Passador, L., Tucker, K. D., Guertin, K. R., Journet, M. P., Kende, A. S., and Iglewski, B. H. (1996).** Functional analysis of the *Pseudomonas aeruginosa* autoinducer PAI. *J Bacteriol* **178**, 5995-6000.
- Pearson, J. P., Gray, K. M., Passador, L., Tucker, K. D., Eberhard, A.,**
- 35 **Iglewski, B. H., and Greenberg, E. P. (1994).** Structure of the autoinducer

- required for expression of *Pseudomonas aeruginosa* virulence genes. *Proc Natl Acad Sci U S A* **91**, 197-201.
- Pearson, J. P., Passador, L., Iglewski, B. H., and Greenberg, E. P. (1995).** A second *N*-acylhomoserine lactone signal produced by *Pseudomonas*
- 5 *aeruginosa*. *Proc Natl Acad Sci U S A* **92**, 1490-1494.
- Pearson, J. P., Pesci, E. C., and Iglewski, B. H. (1997).** Roles of *Pseudomonas aeruginosa las* and *rhl* quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. *J Bacteriol* **179**, 5756-5767.
- Pedersen, S. S., Hoiby, N., Espersen, F., and Koch, C. (1992).** Role of
- 10 alginate in infection with mucoid *Pseudomonas aeruginosa* in cystic fibrosis. *Thorax* **47**, 6-13.
- Pesci, E. C. and Iglewski, B. H. (1997).** The chain of command in *Pseudomonas* quorum sensing. *Trends Microbiol* **5**, 132-134.
- Pesci, E. C., Milbank, J. B., Pearson, J. P., McKnight, S., Kende, A. S.,**
- 15 **Greenberg, E. P., and Iglewski, B. H. (1999).** Quinolone signalling in the cell-to-cell communication system of *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* **96**, 11229-11234.
- Piper, K. R., von Bodman, S. B., and Farrand, S. K. (1993).** Conjugation factor of *Agrobacterium tumefaciens* regulates Ti plasmid transfer by
- 20 autoinduction. *Nature* **362**, 448-450.
- Pollack, M. (1990)** *Pseudomonas aeruginosa*. In *Principles and Practice of Infectious Diseases*, pp. 1673-1691. Edited by G. L Mandell, R. G. Douglas, and J. E. Bennett. New York, NY: Churchill Livingstone Inc.
- Rasmussen, T. B., Manefield, M., Andersen, J. B., Eberl, L., Anthoni, U.,**
- 25 **Christophersen, C., Steinberg, P., Kjelleberg, S., and Givskov, M. (2000).** How *Delisea pulchra* furanones affect quorum sensing and swarming motility in *Serratia liquefaciens* MG1. *Microbiology* **146**, 3237-3244.
- Reichelt, J. L. and Borowitzka, M. A. (1984).** Antimicrobial activity from marine algae: results of a large-scale screening programme. *Hydrobiology*
- 30 **116/117**, 158-168.
- Reimmann, C., Beyeler, M., Latifi, A., Winteler, H., Foglino, M., Lazdunski, A., and Haas, D. (1997).** The global activator GacA of *Pseudomonas aeruginosa* PAO positively controls the production of the autoinducer *N*-butyryl-homoserine lactone and the formation of the virulence factors pyocyanin,
- 35 cyanide, and lipase. *Mol Microbiol* **24**, 309-319.

- Rust, L., Pesci, E. C., and Iglewski, B. H. (1996).** Analysis of the *Pseudomonas aeruginosa* elastase (*lasB*) regulatory region. *J Bacteriol* **178**, 1134-1140.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989).** *Molecular cloning : A laboratory manual 1-3*, 2.ed. edn. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press.
- Schlichtman, D., Kubo, M., Shankar, S., and Chakrabarty, A. M. (1995).** Regulation of nucleoside diphosphate kinase and secretable virulence factors in *Pseudomonas aeruginosa*: roles of *algR2* and *algH*. *J Bacteriol* **177**, 2469-2474.
- Schweizer, H. P. (1991).** Improved broad-host-range *lac*-based plasmid vectors for the isolation and characterization of protein fusions in *Pseudomonas aeruginosa*. *Gene* **103**, 87-92.
- Seed, P. C., Passador, L., and Iglewski, B. H. (1995).** Activation of the *Pseudomonas aeruginosa lasI* gene by LasR and the *Pseudomonas* autoinducer PAI: an autoinduction regulatory hierarchy. *J Bacteriol* **177**, 654-659.
- Singh, P. K., Schaefer, A. L., Parsek, M. R., Moninger, T. O., Welsh, M. J., and Greenberg, E. P. (10-12-2000).** Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. *Nature* **407**, 762-764.
- Swift, S., Throup, J. P., Williams, P., Salmond, G. P., and Stewart, G. S. (1996).** Quorum sensing: a population-density component in the determination of bacterial phenotype. *Trends Biochem Sci* **21**, 214-219.
- Toder, D. S., Ferrell, S. J., Nezezon, J. L., Rust, L., and Iglewski, B. H. (1994).** *lasA* and *lasB* genes of *Pseudomonas aeruginosa*: analysis of transcription and gene product activity. *Infect Immun* **62**, 1320-1327.
- Toder, D. S., Gambello, M. J., and Iglewski, B. H. (1991).** *Pseudomonas aeruginosa* LasA: a second elastase under the transcriptional control of *lasR*. *Mol Microbiol* **5**, 2003-2010.
- Van Delden, C. and Iglewski, B. H. (1998).** Cell-to-cell signalling and *Pseudomonas aeruginosa* infections. *Emerg Infect Dis* **4**, 551-560.
- von Bodman, S. B. and Farrand, S. K. (1995).** Capsular polysaccharide biosynthesis and pathogenicity in *Erwinia stewartii* require induction by an *N*-acylhomoserine lactone autoinducer. *J Bacteriol* **177**, 5000-5008.
- West, S. E. H., Schweizer, H. P., Dall, C., Sample, A. K., and Runyen-Janecky, L. J. (1994).** Construction of improved *Escherichia-*

Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in *Pseudomonas aeruginosa*. *Gene* **148**, 81-86.

- 5 **Whiteley, M., Lee, K. M., and Greenberg, E. P. (1999).** Identification of genes controlled by quorum sensing in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* **96**, 13904-13909.

Whiteley, M., Parsek, M. R., and Greenberg, E. P. (2000). Regulation of quorum sensing by RpoS in *Pseudomonas aeruginosa*. *J Bacteriol* **182**, 4356-4360.


- 10 **Williams, P., Camara, M., Hardman, A., Swift, S., Milton, D., Hope, V. J., Winzer, K., Middleton, B., Pritchard, D. I., and Bycroft, B. W. (2000).** Quorum sensing and the population-dependent control of virulence. *Philos Trans R Soc Lond B Biol Sci* **355**, 667-680.

- 15 **Winson, M. K., Camara, M., Latifi, A., Foglino, M., Chhabra, S. R., Daykin, M., Bally, M., Chapon, V., Salmond, G. P., Bycroft, B. W., Lazdunski, A., Stewart, G. S. A. B., and Williams, P. (1995).** Multiple *N*-acyl-L-homoserine lactone signal molecules regulate production of virulence determinants and secondary metabolites in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* **92**, 9427-9431.

- 20 **Wu, H., Song, Z., Hentzer, M., Andersen, J. B., Heydom, A., Mathee, K., Moser, C., Eberl, L., Molin, S., Hoiby, N., and Givskov, M. (2000).** Detection of *N*-acylhomoserine lactones in lung tissues of mice infected with *Pseudomonas aeruginosa*. *Microbiology* **146**, 2481-2493.

CLAIMS:


1. A method of degrading or causing sloughing of a biofilm, the method comprising applying to the biofilm at least one compound of general formula I:



wherein R₁ is selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

R₂, R₃ and R₄, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl, arylalkyl, or a silyl group, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;


R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane; and " " represents a single bond or a double bond, or a compound of general formula II



wherein R₅, R₆ and R₇, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, carboxyl, acyl, acyloxy, acylamino, formyl and cyano whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic, hydrophobic or fluorophilic and X is a halogen.

2. A method of degrading or causing sloughing of a *Pseudomonas* biofilm in the lung of a subject suffering from cystic fibrosis, the method comprising administering to the biofilm at least one compound of general formula I:

55




5 wherein R_1 is selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

10 R_2 , R_3 and R_4 , which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl, arylalkyl, or a silyl group, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

15 R_3 or $R_4 + R_2$ can be a saturated or an unsaturated cycloalkane; and " " represents a single bond or a double bond.

or a compound of general formula II



20 wherein R_6 and R_7 are independently H, halogen, carboxyl, ester, formyl, cyano, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

25 X is a halogen;

R_5 is H, alkyl, alkenyl, alkynyl, alkene, alkyne, aryl, arylalkyl, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic.

3. A method according to claim 1 for treating a disease or infection in a human or animal subject in which a biofilm is formed, the method comprising administration to the subject of a therapeutically or prophylactically effective amount of the composition.


5

4. A method according to claim 3, wherein the disease or infection is selected from periodontal disease, tooth decay, prostate infections, kidney stones, tuberculosis, Legionnaire's disease, an infection of the middle ear, burn and/or wound infection.

10

5. A method according to any one of claims 1 to 5, wherein the method involves treating an immuno-compromised individual.

6. A biofilm degrading or sloughing composition comprising an amount of a compound comprising at least one compound of general formula I:




wherein R₁ is selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

R₂, R₃ and R₄, which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, acyl, alkenyl, aryl, alkylaryl, arylalkyl, or a silyl group, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

R₃ or R₄ + R₂ can be a saturated or an unsaturated cycloalkane; and " " represents a single bond or a double bond, or a compound of general formula II

30

57



II


wherein R_5 , R_6 and R_7 , which may be the same or different, are independently selected from H, halogen, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, carboxyl, acyl, acyloxy, acylamino, formyl and cyano whether

- 5 unsubstituted or substituted, optionally interrupted by one or more hetero atoms, straight chain or branched chain, hydrophilic, hydrophobic or fluorophilic and X is a halogen,


wherein the amount of the compound(s) in the composition is effective to degrade or cause sloughing of at least a part of the biofilm.

10

7. A method or composition of any one of the preceding claims, wherein the compound comprises at least compound of the formula:



15



8. The composition of claim 6 or 7, additionally comprising a surfactant selected from the group consisting of anionic, nonionic, amphoteric, biological
- 10 surfactants and mixtures thereof.

9. The composition of claim 8, wherein the surfactant is sodium dodecyl sulfate.
10. A composition of any one of claims 6 to 9, further comprising a
5 compound selected from the group consisting of biocides, fungicides, antibiotics, and mixtures thereof.
11. A method of removing biofilm at least in part from a surface comprising the step of applying a cleaning-effective amount of the composition of
10 according to any one of claim 6 to 10 to a biofilm containing surface.
12. A method of claim 11, wherein the surface is a hard, rigid surface.
13. A method of claim 12, wherein the surface is selected from the group
15 consisting of a drainpipe, glaze, ceramic, porcelain, glass, metal, wood, chrome, plastic, vinyl, formica, flooring, and operating theatre surfaces.
14. A method of claim 11, wherein the surface is a soft, flexible surface.
- 20 15. A method of claim 14, wherein the surface is selected from the group consisting of shower curtains or liners, upholstery, laundry, and carpeting.
16. A method or composition according to any one of the preceding claims, wherein the biofilm comprises a bacteria selected from the class
25 *Pseudomonas*, *Staphylococcus*, *Aeromonas*, *Burkholderia*, *Erwinia*, *Fusobacterium*, *Helicobacter*, *Klebsiella*, *Listeria*, *Mycobacterium*, *Neisseria*, *Porphyromonas*, *Providencia*, *Ralstonia*, *Salmonella*, *Streptococcus*, *Vibrio*, *Xenorhabdus*, and *Yersinia* and combinations of two or more thereof.
- 30 17. A method according to claim 16, wherein the bacteria is selected from at least one of the group consisting of *Aeromonas hydrophilia*, *A. salmonicida*, *Burkholderia cepacia*, *Enterobacter aerogenes*, *Escherichia coli*, *Erwinia carotovora*, *Fusobacterium nucleatum*, *Helicobacter pylori*, *Klebsiella pneumonia*, *Listeria monocytogenes*, *Mycobacterium tuberculosis*, *Neisseria meningitidis*, *N. gonorrhea*, *Porphyromonas gingivalis*, *Providencia stuartii*,
35 *Pseudomonas aeruginosa*, *Ralstonia solanacearum*, *Salmonella typhimurium*,

Salmonella choleraesuis, *Serratia liquefaciens*, *S. marcesens*, *Staphylococcus aureus*, *S. epidermidis*, *Streptococcus mutans (sobrinus)*, *Strep. pyogenes*, *Strep pneumonia*, *Vibrio parahaemolyticus*, *V. vulnificus*, *V. cholerae*, *V. harveyi*, *V. anguillarum*, *Xenorhabdus nemotophilus*, *Yersinia pestis*, *Y.*

5 *enterocolitica*, and *Y. pseudotuberculosis*

18. A dentifrice comprising an effective amount of a composition of claim 6.

19 A mouthwash comprising an effective amount of a composition of claim
10 6.

20. A method for treatment of dental caries comprising administering an effective amount of a composition of claim 6.

15 21. A method of prevention of dental caries comprising administering an effective amount of a composition of claim 6.

22. A method of treatment of acne comprising topically administering an effective amount of a composition of claim 6.

20

23. A composition according to claim 6, useful for flushing a catheter and having activity against microorganisms in established biofilms.

24. A composition according to claim 23 further comprising a biocide and/or
25 an antibiotic.

25. A method of treating a medical indwelling device having a biofilm formed on at least a part of a surface thereof, the method comprising contacting the device with a composition in accordance with claim 6.

30

26. A method according to claim 25, wherein the indwelling device is selected from the group consisting of bone prostheses, surgical pins, heart valves, pacemakers and the like.

27. A method for inhibiting microbially influenced corrosion of microbially influenced corrosion-susceptible metal surfaces having an anaerobic biofilm

containing active sulfate-reducing bacteria comprising contacting the biofilm with a composition according to claim 6.

28. A method of removing biofilm from the surfaces of conduit comprising contacting at least part of the conduit surface with a composition according to claim 6.

29. A method according to claim 28, wherein the method further comprises means to induce turbulence to assist in removal of the biofilm.

30. A method according to claim 28 or 29, wherein the composition is introduced into the conduit with one or more surfactants.

31. A method according to any one of claims 28 to 30, wherein the conduits are piping conduits in industrial facilities or in household plumbing systems.



32. A method of treating a biofilm in a cooling water system comprising contacting at least part of a cooling water in the system with a composition in accordance with claim 6.

33. A method according to claim 32, wherein the cooling system is that used in power-generating plants, refineries, chemical plants, or air conditioning systems and the like

34. An ophthalmic composition for treating biofilm formation comprising an effective amount of a composition according to claim 6, and a bactericidal agent to kill individual bacteria that are released from the biofilm structure as it is being degraded or sloughed.


35. A composition as claimed in claim 34 wherein the bactericidal agent is selected from the group consisting of: aminoglycoside antibiotic; a quinolone or fluoroquinolone antibiotic; a cephalosporin antibiotic; a penicillin antibiotic; and tobramycin.

36. A composition as claimed in claim 35, wherein the bactericidal agent is selected from the group consisting of: ciprofloxacin, ofloxacin, aztreonam, vancomycin, streptomycin, neomycin, and gentamicin.
- 5 37. An ophthalmic composition according to claim 35, which is suitable for treating an infection of the eye.
38. A method of cleaning and disinfecting a contact lens comprising contacting the lens with an effective amount of a composition of claim 6.
- 10 39. A method according to claim 38, wherein the composition is in the form of a saline solution.
40. A method according to claim 11, wherein the surface is a living surface.
- 15 41. A method according to claim 40, wherein the surface is a tissue, membrane or skin.



2/3

A



B





Fig. 3

C



D






Fig. 4

Fig. 5






Fig. 1





Fig. 2



INTERNATIONAL SEARCH REPORT

 International application No.
PCT/AU02/00797

| | | | | | |
|--|--|-----------------------|--|--|--|
| A. CLASSIFICATION OF SUBJECT MATTER | | | | | |
| Int. Cl. ⁷ : A61K 31/365, 31/695, 31/121, 31/19, A61P 31/04, A01N 43/08, 37/42, 35/02 | | | | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | | | | |
| B. FIELDS SEARCHED | | | | | |
| Minimum documentation searched (classification system followed by classification symbols) | | | | | |
| REFER ELECTRONIC DATA BASE CONSULTED BELOW | | | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | | | | |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) | | | | | |
| DWPI, REGISTRY/CAPLUS: Keywords: furanone, biofilm | | | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | | | |
| X | WO 9953915 A (UNISEARCH LIMITED) 28 October 1999 Entire document | 1-41 | | | |
| X | WO 9629392 A (UNISEARCH LIMITED) 26 September 1996 Entire document, Figs 1-3, claim 17 | 1-41 | | | |
| X | WO 9601294 A (UNISEARCH LIMITED) 18 January 1996 Abstract, Figs 1-3 | 1-41 | | | |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex | | | | | |
| <table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 33%; vertical-align: top;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> <td style="width: 33%;"></td> </tr> </table> | | | * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family | |
| * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family | | | | |
| Date of the actual completion of the international search 12 July 2002 | Date of mailing of the international search report 19 JUL 2002 | | | | |
| Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929 | Authorized officer TERRY SUMMERS Telephone No : (02) 6283 3126 | | | | |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/00797

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|---|---|-----------------------|
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | McConnell O.J. <i>et al.</i> , Polyhalogenated 1-octene-3-ones, antibacterial metabolites from the red seaweed <i>Bonnemaisonia asparagoides</i> , <i>Tetrahedron Letters</i> , 1977, No. 22, 1851-1854 Table 1, page 1851 lines 8-10 of text | 1-41 |
| X | Fenical W. <i>et al.</i> , Antibiotics and antiseptic compounds from the family <i>Bonnemaisoniaceae</i> (<i>Florideophyceae</i>), Proceedings of the International Seaweed Symposium, Volume Date 1977, 9 th 1979, Issue Date 1979, 387-400 Abstract, pp 389-391 and 397 | 1-41 |
| X | Ren D. <i>et al.</i> , Inhibition of multicellular behavior of <i>Escherichia coli</i> and <i>Bacillus subtilis</i> by 4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone, Abstr. Pap., Am. Chem. Soc. (3 April 2001), 221st, BIOT-094 Entire abstract | 1-41 |
| P,X | WO 0143739 A1 (UNISEARCH LIMITED) 21 June 2001 Claims 1,5 and 25 | 1-41 |
| P,X | WO 0176594 A1 (UNISEARCH LIMITED) 18 October 2001 Page 3 lines 5-13, Table 3 page 17, claim 5 | 1-41 |
| P,X | WO 0168090 A1 (UNISEARCH LIMITED) 20 September 2001 Claims | 1-41 |
| P,X | WO 0200639 A1 (UNISEARCH LIMITED) 3 January 2002 Page 43 line 26-page 44 line 2, table 1 page 45 | 1-41 |
| P,X | WO 0247681 A1 (UNISEARCH LIMITED) 20 June 2002 Claims 14, 15 and 31 | 1-41 |
| P,X | WO 0185664 A2 (PRINCETON UNIVERSITY <i>et al.</i>) 15 November 2001 Pages 27-29, page 31 lines 4-10, compound IV page 32 | 1-41 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/00797

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent Document Cited in Search Report | | Patent Family Member | | | | | |
|---|-----------|----------------------|------------|----|-----------|----|--------------|
| WO | 9953915 | AU | 33224/99 | EP | 1071416 | | |
| WO | 9629392 | AU | 49996/96 | BR | 9607661 | CA | 2215797 |
| | | CN | 1185173 | EP | 815201 | NZ | 303630 |
| | | US | 2002037578 | | | | |
| WO | 9601294 | CN | 1156471 | AU | 28750/95 | CA | 2192955 |
| | | EP | 769039 | HK | 1001287 | NZ | 289025 |
| | | US | 6060046 | | | | |
| WO | 200143739 | AU | 200123284 | | | | |
| WO | 200176594 | AU | 20006812 | AU | 200148145 | | |
| WO | 200168090 | AU | 20006292 | AU | 200140373 | | |
| WO | 200200639 | AU | 20008419 | AU | 200167155 | | |
| WO | 200247681 | AU | 20002090 | | | | |
| WO | 200185664 | AU | 200159734 | | | | |
| | | | | | | | END OF ANNEX |